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ABSTRACT 
There is growing interest in how genetic and environmental risk factors interact to confer risk 
for dysregulated iron homeostasis, which is considered a possible pathogenic mechanism in 
multiple sclerosis (MS). While iron deficiency has been associated with greater disability and 
disease progression, cerebral accumulation and overload of insoluble iron has also been 
reported in MS patients. Variation in the matriptase-2 (TMPRSS6) gene has recently been 
described that may lead to reduced iron levels, which raised the question of whether it may 
be involved in dysfunctional iron regulation as a pathogenic mechanism in MS.   
 
The aims of the study were as follows: 1)) comparison of the allele frequencies and genotype 
distribution for TMPRSS6 A736V (rs855791, c.2207C>T) and HFE C282Y (rs1800562, 
c.845G>A) between patients diagnosed with MS and unaffected controls; 2) determination of 
the effects of clinical characteristics, relevant lifestyle factors and genotype on serum iron 
parameters in MS patients compared to population matched controls; and 3) determination of 
clinical outcome in relation to age of onset and degree of disability in MS patients. 
 
The study population included 121 Caucasian MS patients and 286 population-matched 
controls. Serum iron, transferrin, ferritin and transferrin saturation levels were available from 
previous studies and lifestyle factors were subsequently documented in a subgroup of 68 MS 
patients and 143 controls using the study questionnaire. Genotyping of TMPRSS6 A736V 
and HFE C282Y were performed using allele-specific TaqMan technology. 
 
The genotype distribution and allele frequencies of TMPRSS6 A736V and HFE C282Y did 
not differ between MS patients and controls. MS patients homozygous for the iron-lowering 
minor T-allele of TMPRSS6 A736V had significantly lower serum iron levels (p=0.03) and 
transferrin saturation levels (p=0.03) compared to CC homozygotes. In MS patients the iron-
loading minor A-allele of HFE C282Y was also associated with a paradoxical decrease in 
serum ferritin (p<0.01) compared to GG homozygotes. When considering the combined 
effect of the minor alleles of TMPRSS6 A736V and HFE C282Y with opposite effects on iron 
levels, we found a significant reduction in serum ferritin levels (p<0.05), independent of age, 
sex, body mass index (BMI) or dietary red meat intake in MS patients. A similar effect was 
not observed in the population- and age-matched controls. Higher dietary red meat intake 
correlated significantly with increased ferritin only in controls (p=0.01 vs. 0.21 for MS 
patients). In the presence of the minor allele of HFE C282Y, the TMPRSS6 A736V CT and 
TT genotypes were associated with a significantly earlier age of onset of MS when the post 
hoc test was applied (p=0.04). 
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All the study aims were successfully accomplished. Our results support the possibility of an 
epistatic effect between TMPRSS6 A736V and HFE C282Y associated with reduced ferritin 
levels in MS patients. Pathology-supported genetic testing (PSGT) applied in this study as a 
new concept for analysis of complex diseases with a genetic component, is well placed to 
optimise clinical management in patients with MS.  
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OPSOMMING  
Daar heers toenemende belangstelling in hoe die wisselwerking tussen genetiese en 
omgewingsfaktore die risiko tot wanregulering van yster-homeostase beïnvloed. 
Laasgenoemde is ‘n moontlike patogeniese meganisme vir meervoudige sklerose (MS). 
Alhoewel verhoogde gestremdheid en siekteprogressie met ystertekort geassosieer is, is 
ysterophoping in die serebrum asook ‘n oormaat onoplosbare yster al by MS-pasiënte 
gevind. Variasie in die matriptase-2 (TMPRSS6) geen wat tot verlaging in ystervlakke kan lei, 
is onlangs beskryf en laat die vraag ontstaan of dit betrokke is by wanregulering van yster-
homeostase as patogeniese meganisme in MS. 
 
Die doelwitte van die studie was as volg: 1) vergelyking van alleelfrekwensies en 
genotipeverspreiding vir TMPRSS6 A736V (rs855791, c.2207C>T) en HFE C282Y 
(rs1800562, c.845G>A) tussen MS-pasiënte en ongeaffekteerde kontroles; 3) bepaling van 
die effekte van kliniese indikators, relevante leefstylfaktore en genotipe op serum yster 
parameters in MS-pasiënte in vergelyking met populasie-ooreenstemmende kontroles; en 4) 
bepaling van kliniese uitkoms ten opsigte van aanvangsouderdom en graad van MS-
aantasting. 
 
Die studiepopulasie het uit 121 kaukasiese MS-pasiënte en 286 kontroles van dieselfde 
populasie, wat nie die siekte het nie, bestaan. Serum yster, transferrin, ferritien en 
transferrien-versadigingsvlakke was beskikbaar vanaf vorige studies. Leefstylfaktore is in ‘n 
subgroep van 68 MS-pasiënte en 143 kontroles gedokumenteer met behulp van die studie-
vraelys. TMPRSS6 A736V en HFE C282Y genotipering is met alleel-spesifieke TaqMan-
tegnologie uitgevoer.  
 
Beide pasiënte en kontroles het dieselfde genotipeverspreiding en alleelfrekwensies getoon. 
Die A-alleel van HFE C282Y is met ‘n paradoksale verlaging in serum ferritien geassosieer 
(p<0.01) in MS-pasiënte met TMPRSS6 A736V, moontlik weens geen-geen interaksie wat 
nie deur ouderdom, liggaamsmassa-indeks of inname van rooivleis in die dieet beïnvloed is 
nie (p<0.05) en nie by kontroles gevind is nie. MS-pasiënte wat homosigoties is vir die T-
alleel van TMPRSS6 A736V, het statisties betekenisvolle laer serum ystervlakke (p=0.03) en 
transferrienversadiging (p=0.03) getoon in vergelyking met CC-homosigote. In MS-pasiënte 
was die yster-oorlading A-alleel van HFE C282Y ook geassosieer met ‘n paradoksale 
afname in serum ferritien (p<0.01) in vergelyking met GG-homosigote. Wanneer die 
gekombineerde effek van die risiko-geassosieerde allele van TMPRSS6 A736V en HFE 
C282Y met teenoorgestelde effekte op ystervlakke geanaliseer word, is daar ‘n statisties 
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beteknisvolle afname in serum ferritienvlakke (p<0.05), onafhanklik van ouderdom, geslag, 
liggaamsmassa-indeks of rooivleisinname in MS-pasiënte. ‘n Soortgelyke effek is nie 
waargeneem in populasie- en geslag-gelyke kontroles nie. Die inname van rooivleis in die 
dieet was betekenisvol minder by MS-pasiënte teenoor kontroles (p=0.03) en dit het slegs 
betekenisvol met verhoogde ferritien by kontroles gekorreleer (p=0.01 teenoor 0.21 by MS-
pasiënte). In die teenwoordigheid van die risiko-geassosieerde alleel van HFE C282Y, is die 
TMPRSS6 A736V CT en TT genotipes geassosieer met ‘n statisties-betekenisvolle vroeër 
aanvangsouderdom van MS soos bepaal met die post hoc-toets (p=0.04). 
 
Al die doelwitte van die studie is suksesvol uitgevoer. Die resultate ondersteun die 
moontlikheid van ‘n epistatiese effek tussen TMPRSS6 A736V en HFE C282Y wat 
geassosieer is met ‘n verlaging in ferritienvlakke in MS-pasiënte. Patologie-gesteunde 
genetiese toetsing soos toegepas in hierdie studie as ‘n nuwe konsep vir analise van 
komplekse siektes met ‘n genetiese komponent, is goed geplaas om kliniese hantering van 
MS-pasiënte te optimaliseer. 
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Chapter 1: Literature Review 
1.1 INTRODUCTION 
Multiple Sclerosis (MS) is a chronic neurological disease first described by the French 
neurologist Jeane-Martin Charcot in 1868.  Pathologically MS is characterised by the 
presence of diffuse inflammation and plaques of demyelination throughout the central 
nervous system (CNS), leading to functional impairment, reduced quality of life, morbidity 
and early mortality due to MS (Dutta and Trapp 2007; Zwibel, 2009).  
 
Despite more than 50 years of concerted investigative effort, the underlying pathophysiology 
of MS known to involve a series of complex interactions between environmental factors 
acting upon a susceptible genotype, remains incompletely understood. There is also growing 
appreciation for its heterogeneity in geographic and ethnic distribution, clinical presentation, 
prognosis and treatment response (Taylor et al. 2010). Furthermore, mounting evidence 
suggests that clinical and genetic sub-types of this disease exist; raising the possibility that 
individualized treatment of these groups could be therapeutically beneficial. Several studies 
confirmed the marked inter-patient variance in clinical presentation and therapeutic response 
to disease-modifying treatments (DMTs) in MS patients (Axtell et al. 2010; Stewart and Vu 
Tran, 2012). A homogeneous system of classification based on diagnostic hierarchy could 
therefore obscure subtle differences in presentation that may require individualised 
treatment. 
 
Consistent with the notion that certain sub-groups of MS exist, previous studies performed in 
South Africa highlighted the role of deranged iron homeostasis as a pathogenic mechanism 
in MS, dependent on poorly understood and complex interactions between genetic and 
environmental risk factors  (Kotze et al. 2001; Kotze et al. 2006, van Rensburg et al. 2012). 
On the one hand, myelin production and maintenance requires a continuous supply of iron 
and other micronutrients to oligodendrocytes in the central nervous system (the cells that 
synthesise myelin); a process which is tightly controlled and dependent on the concerted and 
balanced activity of many regulatory proteins such as ferritin and transferrin (Todorich et al. 
2009). Conversely, the presence of insoluble iron deposits demonstrated via magnetic 
resonance imaging (MRI) in demyelinating plaques and their constituents in MS has been 
linked to its pathogenesis, while these do not contribute towards cerebral iron bioavailability. 
This may result in iron deficiency and suboptimal myelination capacity by oligodendrocytes 
(Rouault and Cooperman 2006). Clinical implications of the apparent “iron paradox” in MS 
posing a significant challenge regarding our understanding of the pathogenesis of this 
disease, has recently been addressed in an editorial by van Rensburg and van Toorn (2010) 
and a review by van Rensburg et al. (2012). 
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Chapter 1: Literature Review 
The specific research question leading to the current study was whether genotyping for low-
penetrance mutations or functional single nucleotide polymorphisms (SNPs) involved in iron 
homeostasis would be clinically useful to identify a subgroup of MS patients with altered 
requirements of iron intake in the diet. Clinical relevance of SNPs depends on the 
environment and interaction with other genes; therefore lifestyle factors and relevant 
biochemical parameters also need to be considered in addition to the medical and family 
history of patients when genetic testing is performed. The limitations of genetic testing 
related to many iron-related disorders may be overcome when performed within a pre-
defined clinical profile, obtained using biochemical testing, to assess the phenotype 
expression of a gene and to monitor response to treatment (Kotze et al. 2009). The ultimate 
aim is to effectively reduce the cumulative effect of multiple risk factors associated with the 
onset and progression of the disease process. 
 
1.2. EPIDEMIOLOGY OF MS  
Both neurodegenerative and autoimmune processes have been implicated in the 
pathogenesis of MS (Roach, 2004; Compston and Coles, 2008), involving multiple complex 
interactions between genetic and environmental risk factors (Ramagopalan et al. 2008; 
Healy et al. 2009). The primary pathological characteristics of MS include diffuse 
inflammation and plaques of axonal demyelination throughout the cerebrum, cerebellum, 
brainstem, optic nerves and spinal cord. The latter may be triggered when the capacity for 
compensatory remyelination in the CNS is exceeded (Bo et al. 2006; Trapp and Nave, 2008; 
Dutta and Trapp, 2011; Antony et al. 2011; Van Horssen et al. 2011). Growing interest in the 
possible role of iron deficiency as a contributory factor in disease onset and/or progression 
(Rooney et al. 1999; Van Rensburg et al. 2006, 2012) is supported by predominance of MS 
in females compared with males (Byun et al. 2008; Koch-Henriksen, 2010). 
 
MS affects more than 2.5 million people globally and places a severe emotional and financial 
burden on families, caregivers and society at large (Paty et al. 1997; Zwibel, 2009; Gandhi et 
al. 2010; Taylor et al. 2010; Dutta and Trapp, 2011). MS is more prevalent in high latitude 
regions, with higher disease prevalence rates reported in Europe, Canada, the United States 
of America, New Zealand as well as several parts of Australia (Modi et al. 2008; 
Kakalacheva et al. 2011). Lower prevalence rate has been favouring countries such as 
Japan and South Africa that are closer to the equator (Ross, 1998; Ascherio and Munger, 
2007; Kakalacheva et al. 2011). However, in South Africa the prevalence of MS has 
increased since previously reported (Dean, 1967; Bird and Satoyoshi, 1975; Naing et al. 
2006), and approximately 23000 people may be affected by MS (Du Toit, 2006).  
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The frequency of MS is unevenly distributed among racial groupings (Byun et al. 2008; 
Ebers, 2008; Simpson et al. 2011), predominantly affecting Caucasians (mainly those of the 
European origin) compared to the Asian population while it is very rare in African 
subpopulations (Modi et al. 2008). Several prevalence studies in South Africa have shown 
that MS occurs in all ethnic subgroups, but with very wide frequency distributions amongst 
African blacks, mixed-ancestry, Indians and Caucasians (English and Afrikaans speaking), 
with observed prevalence rates per 100 000 people of 0.23, 1.72, 7.15 and 25.64, 
respectively (Bhigjee et al. 2007). This shows that MS prevalence has increased in South 
Africa since it was first documented by Dean (1967). Unevenness in frequency distributions 
of MS between the diverse racial groupings (Caucasians versus Africans), together with the 
high prevalence of other chronic neurological disorders such as acute disseminated 
encephalomyelitis (ADEM) amongst African populations, may partly reflect differences in 
genetic background between populations (Weinstock-Guttman et al. 2003).  
 
1.3. DIAGNOSIS 
MS is difficult to diagnose due to the heterogeneity of the disease and other diseases 
mimicking MS (Polman et al. 2005). There are at present no symptoms, physical findings or 
laboratory tests that can be used to diagnose MS. The diagnosis is therefore made by 
neurologists using a combination of tests, by assessing personal history, clinical symptoms 
and MRI, evoked potentials and analysis of spinal fluid. The severity of disability is measured 
using a neurological exam called the Kurtzke Expanded Disability Status Scale (EDSS) 
(Kurtzke, 1983).  
  
1.3.1. The McDonald Diagnostic Criteria  
Patients are diagnosed according to the McDonald criteria by their respective neurologists 
so that when they join the MS research programme at Tygerberg, they were already 
diagnosed. The McDonald diagnostic criteria, updated and revised in 2005 by an 
international panel on diagnosis of MS (Polman et al. 2005), contain guidelines used for the 
clinical diagnosis of MS (McDonald et al. 2001). These include the detection of multiple foci 
of demyelination in the CNS, and evidence of dissemination in time and space of lesions 
typical of MS, i.e. evidence of damage in at least two separate areas of the CNS, which 
includes the brain, spinal cord and optic nerves as well as evidence that the damage 
occurred at least one month apart. The guidelines are used to confirm a definite MS 
diagnosis with a recommendation list including clinical presention with two or more episodes 
of neurological disturbance and objective clinical evidence for more than two lesions. For 
clinical presentation with two or more attacks and objective clinical evidence of one lesion, 
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recommended additional tests include two or more MRI-detected lesions and positive CSF 
analysis (detection of oligoclonal bands), or dissemination in space demonstrated by MRI 
with the fulfilment of at least three lesion appearances (Polman et al. 2005). The panel 
recommendations are summarised in appendix B.     
  
1.3.2. Kurtzke EDSS  
 The Expanded Disability Status Scale (EDSS; Kurtzke 1983; Appendix A) is a test that is 
used to determine disability in MS. It is considered to be the “gold standard” for disability 
measurement and it is used in all clinical trials – it is an objective test and can be done by 
any clinician, not necessarily a neurologist. The EDSS value varies over time – people can 
become better or worse over time and as a result of treatment. The scale ranges from 0 (no 
neurological symptoms) to 10 (death due to MS), so the higher the score the greater the 
disability.  
  
The neurological impairment is measured by the total score derived from clinical assessment 
of eight functional systems (FS) primarily affected in this disease, namely pyramidal, 
sensory, visual, cerebral, cerebellar, brainstem and bladder/bowel functioning as well as 
mobility. The original score was expanded and modified to increase its sensitivity for 
detecting changes in disease progression (Kurtzke, 1965). Scores ranging from 0 to 3.5 
indicate impairment in isolated FS, while those ranging from 4.0 to 7.0 indicate difficulty in 
ambulation. A score of greater than 8.0 indicates more severe disability requiring assistance 
in walking and communication (Kurtzke, 1965; Amato and Ponziani, 1999).  
  
Since the EDSS requires a visit of the patient to a clinician, putting constraints on the follow-
up of patients, especially those who have difficulty with ambulation, some studies have 
evaluated the use of novel alternative approaches to disease monitoring, including self-
reported questionnaires and telephonic interviews (Cheng et al. 2001; Lechner-Scott et al. 
2003). An internet-based method has recently been validated (Leddy et al. 2013). 
  
1.3.3. Magnetic Resonance Imaging 
MRI is a sensitive, non-invasive imaging method that can detect lesions in the brain and 
spinal cord (Lassmann et al. 2001, Dutta and Trapp, 2007). It is used for diagnosis and to 
monitor the course of the disease as well as the clinical management of patients with MS 
(Bakshi et al. 2008). During diagnosis, MRI shows lesion dissemination in space and time, 
and can evaluate conditions that can clinically mimic MS (Polman et al. 2005; Charil et al. 
2006). MRI involves assessing lesions using non-contrast longitudinal spin-lattice (T1)- and 
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transverse spin-spin (T2)- weighted images, as well as gadolinium enhanced T1-weighted 
images (Schenck, 2003; Neema et al. 2007). Gadolinium is a contrast agent that is injected 
intravenously to show places where the blood-brain barrier has degraded due to 
inflammation. The enhancement of lesions allows detection of contrast agent accumulated in 
interstitial space (Bakshi et al. 2008). Changes in T1 give an indication of chronic lesions 
which are accompanied by severe axonal loss and swelling, whilst that of T-2 indicates 
disruption of the BBB with or without acute demyelination (Fisher et al. 2007).  
 
1.4. CLINICAL CHARACTERISTICS AND SUBTYPES OF MS 
There  can  be  few  diseases  with  as  much  variation  in  clinical outcome  as  seen  in MS 
(DeLuca et al. 2007). This heterogeneity makes it very difficult to diagnose and treat 
patients. A classification of subtypes was suggested by Lublin and Reingold (1996), which 
included relapsing-remitting (RRMS), secondary progressive (SPMS) and primary 
progressive (PPMS) forms and is still adhered to in order to facilitate the evaluation of 
patients taking part in clinical trials.  
However, patients are heterogeneous in their clinical course and progression, differing with 
regards to age of onset, episode duration and character, symptom severity, risk of 
irreversible neurological damage and functional disability, as well as associated 
neuropathology and capacity for axonal remyelination, and significant interpersonal variance 
(Victor and Ropper, 2001; Byun et al. 2008; Koch-Henriksen and Sorensen, 2010). 
Furthermore, there is no immunological or biochemical test that can reliably be used either to 
diagnose MS or to place patients into disease categories.  
  
The clinical categories were designed to range from less severe disease (RRMS) to greater 
severity (SPMS) to patients with a rapidly progressing course (PPMS). The implication of the 
classification is that patients show progression from less severe to more severe over time, 
and that a reversal of disability is not to be expected; i.e. that the majority of patients with 
RRMS will undergo transition to SPMS, a chronic and progressive disease sub-type 
characterized by minimal periods of remission, while PPMS, a further sub-type, is 
characterized by on-going neurological injury and a progressive accumulation of functional 
disability (Lublin and Reingold, 1996; Vollmer, 2007). However, relapses of acute or sub-
acute onset, during which neurological dysfunction is clinically evident, are often offset by 
periods of partial or complete remission, both being highly variable in frequency and duration 
(Hauser and Oksenberg, 2006; Trapp and Nave, 2008). 
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A recent study by Tremlett et al. (2012) has cast doubt on the assumption of a steady 
progression of disability in MS. They examined 16,132 EDSS scores of patients who were 
not taking immuno-modulatory drugs over one and two years, and found that up to 30 per 
cent of patients experienced improvements in disability as measured by the EDSS. There 
were even improvements in some people with primary progressive MS. Although a benign 
form of MS was not included in the original classification of disease subtypes, several 
authors have pointed out that some patients do not follow the general rule of steady 
progression, but were stable at an EDSS of less than 3 for more than 10 or even 20 years, 
and have suggested that “benign MS” should form a separate category (Pittock et al. 2004). 
However, another study has questioned the validity of “benign MS”, reporting that 
deterioration of cognitive function, fatigue, pain, and depression were detected in some 
patients with benign MS, which had a negative impact on their work and social activities. 
Although newer quantitative MRI techniques show less tissue damage, as well as greater 
repair and compensatory efficiency following MS injury, the authors suggest that currently 
accepted criteria for benign MS diagnosis may cause an overestimation of true prevalence 
(Correale et al. 2012). 
 
 The confusion that exists in the literature concerning the classification of MS subtypes 
based on clinical criteria, as well as deterioration or improvement may possibly be 
addressed by regarding MS from a gene-diet perspective. Davis et al. (2013, 2014) 
demonstrated that identification of low-penetrance genetic risk factors may reinforce the 
importance of adequate fruit, vegetable and folate intake and restriction of saturated/trans fat 
intake in the diet.  Intake of at least five fruits and vegetables per day resulted in a 
favourable lower EDSS with a significant reduction (28%) noted for each extra day at least 
five portions were consumed (Davis et al. 2014). This finding concurs with the findings of a 
recent study by van Rensburg et al. (2013), showing that the EDSS scores of 12 patients 
following a nutrition support programme improved significantly (29.9% decrease in EDSS 
from 3.50 to 2.45; p=0.021), while patients who did not stay on the regimen had a worse 
EDSS score after 6 months (13.9% increase from 4.83 to 5.50). After 7 years, the patients 
who stayed on the programme improved even more to a mean EDSS of 1.4, compared to 
patients not on the programme who had a worse outcome of 8.4 (p < 0.0001). It may 
therefore be that “benign MS” is not a category, but may indicate the outcome of lifestyle 
behaviour. South African MS patients who smoked had a significantly greater EDSS score 
than non-smokers (p < 0.001), which confirms the deleterious effect of smoking on MS 
(Hernan et al. 2005; Di Pauli et al. 2008). 
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Further evidence that clinical categories may be less useful in the genomics era came from a 
study by Kotze et al. (2001), who investigated the relevance of serum iron status in RRMS, 
SPMS and PPMS. While genetic variation in the promoter region of the NRAMP1 gene was 
identified as a risk factor for MS, it was not associated with any of these disease subtypes. 
However, ferritin was significantly lower in RRMS than in PPMS, but after males known to 
have higher iron status compared to females were excluded, the difference between these 
clinical MS subtypes was no longer significant. The relevance of iron deficiency in MS was 
further investigated by van Rensburg et al. (2006), who showed that iron deficiency was 
significantly associated with an earlier age of diagnosis, although the reason for the iron 
deficiency in about 30% of patients was not apparent from their diet. It therefore seems 
possible that genetic subgroups could be identified in that may benefit from altered iron 
intake irrespective of clinical subgroups that are difficult to define and may change over time.  
 
Prolonged disruption of the blood-brain barrier (BBB) is an important trigger for relapse, and 
has been associated with a decreased remission frequency, progressive neurological 
impairment and decline, a reduced capacity for axonal remyelination, and a decreased 
potential for functional recovery (Vollmer, 2007; Trapp and Nave, 2008; Mowry et al. 2009).  
RRMS and progressive disease are characterized by focal and diffuse demyelination 
respectively, with the location of lesions in the central nervous system (CNS) considered a 
partial determinant of disability risk (Compston and Coles, 2008; Mowry et al. 2009; Pithadia 
et al. 2009). MS may present with a wide variety of symptoms occurring either in isolation or 
various combinations, with no single symptom considered pathogenic of the disease state. 
Initial presenting symptoms may include mild weakness, sensory and visual loss, impaired 
co-ordination, fatigue and cognitive dysfunction. As the disease progresses, these may 
extend to complete paralysis, blindness and involuntary loss of bladder and bowel control 
(Lublin and Reingold, 1996; Berti et al. 2000; Gandhi et al. 2010).  
 
1.5. THERAPEUTIC INTERVENTION STRATEGIES FOR MS  
A major limitation in the treatment of MS is that currently available therapies, while reducing 
relapse rate, are ineffective in attenuating the eventual risk of irreversible neurological 
disability (Wingerchuk, 2008; Tullman, 2013). As such, none of the approved MS 
medications are licensed by the FDA for attenuation of disability progression (Tremlett et al. 
2012). Furthermore, many drugs currently used for MS are expensive, of limited availability, 
and associated with a range of adverse side-effects, which has prompted a growing interest 
in the benefits of non-pharmacological measures to improve treatment outcomes in this 
disease (Tullman, 2013). The development of effective and affordable treatment strategies 
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for MS remains an important area of research, consistent with the ultimate aim of the present 
study to formulate individualised harm-reduction strategies for genetically susceptible 
individuals, designated Pathology Supported Gene-based Intervention (van Rensburg et al. 
2012; Kotze et al. 2013). 
 
1.5.1. Disease Modifying Drugs  
Disease-modifying drugs (DMDs) are most commonly used in the context of MS, while the 
related term disease-modifying anti-rheumatic drugs (DMARDs) are used in reference to a 
variety of autoimmune conditions. DMDs work by modulating the immune response and 
limiting BBB permeability and CNS invasion by T lymphocytes. This results in attenuated 
neural tissue injury and demyelination stemming from the increased expression and activity 
of various pro-inflammatory mediators, including cytokines, matrix metalloproteinases and 
cellular adhesion molecules (Wingerchuk et al. 2001). DMDs currently approved by the US 
Food and Drug Administration (FDA) for use in MS include Interferon beta-1 (IFN-β -1a and 
b), Glatiramer Acetate (Copolymer-I/Copaxone) and Mitoxantrone (Novantrone) (Confavreux 
et al. 2003; Pithadia et al. 2009). These drugs have been shown to significantly reduce the 
number of CNS lesions evident on MRI as well as decrease the frequency of relapses and 
reduce the rate of disease progression (Tullman, 2013).  
 
Interferon beta-1 (IFN-β -1a and b) 
The use of Interferon beta is mainly considered for patients who experience frequent 
relapses and show incomplete recovery or accumulation of CNS lesions on MRI (Clanet et 
al. 2002; Panitch et al. 2002). Interferon works by decreasing BBB permeability and 
therefore limiting neural tissue damage by restricting the entry of T lymphocytes into the 
CNS (Comi, 2009; Pithadia et al. 2009; Tullman, 2013). Early initiation of treatment is 
associated with a delayed disability onset as well as reduced rate of disease progression in 
MS, while a delay therein may lead to irreversible neurological impairment (Comi et al. 2001; 
Kappos et al. 2006; Baumhack, 2008; Milo and Panitch, 2010; Tullman, 2013). However, 
such beneficial effects are primarily confined to patients with mono- as compared to multi-
focal CNS lesions, while interferon use is also associated with a host of serious side-effects, 
including myalgia, fatigue, fever, anorexia and insomnia (Comi et al. 2001; Kappos et al. 
2006; Pithadia et al. 2009). 
 
Glatiramer Acetate (Copolymer-I/Copaxone) 
Synthetic polypeptide compounds such as Glatiramer Acetate (Copolymer-I/Copaxone) have 
been shown to reduce the relapse rate in RRMS by almost a third (Steinman, 2007; 
Stellenbosch University  http://scholar.sun.ac.za
9 
Chapter 1: Literature Review 
Baumhack, 2008; Pithadia et al. 2009). Common side-effects associated with the use of 
glatiramer acetate include redness, swelling flushing, shortness of breath, chest pain, 
anxiety and rapid heartbeat (Johnson et al. 2005; Weber et al. 2008). 
 
Methylprednisolone  
Methylprednisolone is a commonly used corticosteroid generally used for the treatment of 
acute relapses, while chronic treatment is considered in progressive MS, with SPMS in 
particular showing clinically favorable outcomes (Hohol et al. 1999; Pithadia et al. 2009). 
While short-course intravenous (IV) methylprednisolone is generally well-tolerated, 
prolonged use is associated with various side-effects, including hypertension, impaired 
glucose tolerance, osteoporosis, increased infection risk, gastric ulcers and oedema 
(Pithadia et al. 2009; Tullman, 2013). 
 
Mitoxantrone (Novantrone)  
Although the use of Mitoxantrone, an anthracenedione with antineoplastic properties, has 
been shown to reduce the number and severity of relapses in chronic and advanced MS by 
up to 67%, its administration is restricted to three years due to the cardiotoxicity associated 
with prolonged use (Hartung et al. 2002; Pithadia et al. 2009). 
 
1.5.2. Dietary and lifestyle modifications / Non-pharmacological Interventions  
Multiple studies have suggested that a well-balanced diet may have a positive impact on 
symptom severity in MS (Frederick, 1973; Payne, 2001; Pithadia et al. 2009; Habek et al. 
2010, Davis et al. 2014). Adequate intake of micronutrients such as iron and vitamin B12 is 
essential for maintenance and optimisation of myelin synthesis and repair, while the 
antioxidant properties of vitamin C and E may effectively limit free radical – mediated 
neuronal damage (Zhang et al. 2001; van Rensburg et al. 2006; Pithadia et al. 2009). 
Lifestyle risk factors such as cigarette smoking have been associated with numerous health 
concerns (Franklin and Nelson, 2003; Riise and Nortvelt, 2003; Ascherio and Munger, 2007). 
In MS, the effect of cigarette smoke has been associated with increased disease risk and 
progression (Healy et al. 2009; Shirani and Tremlett, 2010).  
 
Recent studies performed in South Africa confirmed the deleterious effect of smoking on MS 
disability as assessed by EDSS, with multiple vascular risk factors found to be significantly 
affected by lifestyle factors such as diet and physical activity (Davis et al. 2014). These 
findings may offer a solution to counteract the detrimental effects of the genetic risk factors 
contributing to the development of high homocysteine levels and obesity in MS patients. This 
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is of particular relevance in view of the findings of Sternberg et al. (2013), performed in 
nearly 300 MS patients, which demonstrated higher cardiovascular risk factors with use of 
three major DMDs (IFN-β, Glatiramer acetate, Natalizumab). The use of drugs acting on the 
cardiovascular system (including antihypertensive, hypolipidaemic, antiplatelets) furthermore 
correlated significantly with MS disease severity. These findings support the implementation 
of a non-pharmacological intervention strategy in the resource-poor South African context, 
focused on the iron metabolic pathway in the present study.  
 
1.6.  IRON IN MS 
Iron dysregulation is considered a possible pathogenic mechanism involved in the 
inflammatory process underlying MS. However, it is uncertain whether iron deficiency or iron 
overload has a deleterious effect on disease development and/or progression (Toshdiwal 
and Zarling, 1992; van Rensburg et al. 2012; LeVine et al. 2013). In MS patients a gender 
effect may contribute towards disease susceptibility found to affect more women than men 
(Byun et al. 2008; Koch-Henriksen, 2010). Higher iron levels in blood could have a protective 
effect in men, as opposed to lower iron levels in women which could be predisposing factor 
for increased risk of developing MS.  
 
Biochemical indicators of iron status include serum iron, transferrin, transferrin saturation 
and ferritin (Custer et al. 1995; Benyamin et al. 2009). Glycosylated transferrin binds 2 Fe3+ 
iron atoms and maintains them in a soluble form. Iron saturated transferrin delivers iron to 
the blood stream for distribution to iron requiring pathways for metabolic processes (Aisen, 
2004).  
 
Transferrin saturation (%) is a good indicator of circulating iron in the blood stream, where 
disrupted/imbalanced homeostasis is indicated  by transferrin saturation <16 % or > 45 % 
which are clinical indicators of iron deficiency and iron overload, respectively (Hentze et al. 
2010).  
 
The brain cells that produce myelin, the oligodendrocytes, have a very high requirement for 
iron (van Rensburg et al. 2012; Levine and Chakrabarty, 2004; Bruck, 2005; Compston and 
Coles, 2008), leading to the hypothesis that an increased iron intake could improve myelin 
synthesis and repair in patients with iron deficiency. (Bruck, 2005; Trapp and Nave, 2008; 
Taylor et al. 2010; Van Horseen et al. 2011). About 30% of patients with MS have low iron 
parameters (van Rensburg et al. 2006); however, the reasons for the iron deficiency have 
not been established. These findings have presented researchers and clinicians with the 
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responsibility to develop tests and treatment options which could benefit patients with altered 
dietary requirements due to their genetic background.  
 
1.6.1. Physiology of iron 
Iron is an essential micronutrient required by almost all living organisms and abundant in 
nature, with sources ranging from plants to animal products (Lieu et al. 2001; Cairo et al. 
2006). It is required as a co-factor for numerous enzymes and almost all the biological 
systems in the body require iron for their optimal function. This includes the respiratory 
systems, energy production system, immune system, normal red blood cell synthesis, DNA 
synthesis and cell replication and proliferation (Andrews et al. 1999; Conrad et al. 1999; Le 
and Richardson, 2002). Red blood cells (erythrocytes) require an adequate supply of iron in 
order to enhance oxygen binding to haemoglobin for transportation, while mitochondria 
require a complete iron-sulphur-haem cluster for energy production through oxidative 
phosphorylation (Beard, 2001; Rouault, 2013).  Futhermore, iron is an important nutritional 
element for brain and CSF functions, where it is required for oligodendrocyte maturation 
(Abo-Krysha and Rashed, 2008; Todorich et al. 2009).  
 
Dietary iron exists in two forms, namely heme and non-heme iron, with each form 
determining the rate of its absorption into the body (Conrad and Umbreit, 2000; Lieu et al. 
2001). Heme iron is derived from animal proteins such as hemoglobin and myoglobin as well 
as iron-containing enzymes (Conrad and Umbreit, 2000). This form is more readily 
absorbable as it is taken up directly by the mucosal cells, and its sources include fish, poultry 
and red meat (Lynch et al. 1989; Conrad et al. 1991; Lieu et al. 2001).  
 
Iron status and dietary components such as calcium, casein, phosphates, phytates, 
polyphenols and soybeans, do not influence the absorption rate of heme iron (Lieu et al. 
2001). Several vegetables (beans, lentils, spinach) and fruit (apricots, peanuts, prunes) are 
sources of non-heme iron which has a poorer absorption rate than heme iron, hence 
requiring enhancers (ascorbic acid, citric acid, cysteine glutathione, etc) that promote iron 
absorption (Conrad and Umbreit, 2000). However, the absorption rate of non-heme iron 
becomes three times higher when taken together with heme iron sources in the same meal 
(Geissler and Singh, 2011). Due to its ability to readily exchange electrons, iron exits in three 
distinct oxidation states, namely ferrous (Fe2+), Ferric (Fe3+) and Ferryl (Fe4+) which allows 
reversible binding to several atoms including oxygen, nitrogen and sulphur, depending on 
the biological redox potential (Beard, 2001; Lieu et al. 2001).  
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The body’s main routes for excreting iron include sweating, shedding of skin cells and 
gastrointestinal excretion. These are unregulated mechanisms that lead to daily iron loss in 
humans, of approximately 1.0 mg/day in adult males versus adult females who lose an 
additional 0.5 mg due to menses (Green et al. 1968; Cairo et al. 2006). Optimal iron levels 
are therefore maintained through tightly regulated iron absorption pathways to ensure iron 
homeostasis at both systemic and cellular levels (Hentze et al. 2004; Donovan et al. 2006; 
Bleackley et al. 2009). Some of the regulatory proteins involved are listed in Table 1.1. Iron 
homeostasis is the body’s main mechanism to prevent iron toxicity (Hentze et al 2004) and 
disruption may result in iron deficiency or overload (Hallberg and Hulthen, 2000; Cairo et al. 
2006; McLaren et al. 2011).  
 
 
Table 1.1. Regulatory proteins involved in the iron absorption pathway  
Regulatory Protein Function Cell-Site 
 
References 
Divalent Metal Iron transporter1 
(DMT1) 
Iron import  Duodenal mucosa Andrews, 2000 
Ferroportin (FPN) Iron export 
Enterocyte, hepatocyte, 
Macrophage 
Pietrangelo, 2004 
Transferrin (Tf) Iron transport Plasma Aisen, 2004 
Transferrin receptors (TfRs) Tf iron uptake BBB and CSF endothelial 
Aisen, 2004, Hentze et al. 
2004 
Ferritin (H- and L chains) Iron store, antioxidant Cytosolic , Mitochondrial  
Harrison and Arosio, 1996;  
Levi et al. 2001 
Duodenal cytochrome b (Dcytb) Ferric Reductase Luminal Duodenum  McKie et al. 2001 
Ceruloplasmin (Cp), Copper-
containing Hephaestin (Cu-Heph) 
Ferrous Oxidase Duodenum, Serum 
Hellman and Gitlin, 2002; 
Vulpe et al. 1999 
Hepcidin Systemic iron regulator Hepatocytes, Liver 
Ganz and Nemeth, 2006, 
2012 
Hereditary hemochromatosis (HFE) Hepcidin expression Hepatocytes, Liver  
Feder et al. 1996; Nemeth et 
al.2004 
Matriptase-2 (TMPRSS6) Hepcidin expression Hepatocytes, Liver Du et al. 2008;  
 
 
1.6.2. Systemic and Cellular iron metabolism 
Iron is metabolised and regulated at both the cellular- and systemic levels that are tightly 
controlled by several proteins involved with iron absorption and release (Anderson et al. 
2009; Finberg et al. 2010; Ganz and Nemeth, 2012). Regulatory proteins required for 
absorption of iron by proximal intestinal (small) enterocytes include divalent metal 
transporter 1 (DMT-1/SLC11A2) and Ferroportin 1 (FPN1/SLC40A1) protein. DMT-1, an 
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importer of dietary non-heme iron (Andrews, 2000; Mackenzie and Garrick, 2005) with the 
help of reductase duodenal cytochrome b, converts Fe3+ to Fe2+ iron (Mckie et al 2001). The 
Fe2+ iron undergoes exportation from the duodenal mucosa into the blood-circulation by 
ferroportin FPN1 protein (Anderson et al. 2009; Fuqua et al. 2012). In the systemic 
circulation, hephaestin and ceruloplasmin oxidases help transferrin transporter protein to 
access iron by converting Fe2+ back to the Fe3+ form, which can be loaded onto an apo-
transferrin for distribution to cells (Vulpe et la. 1999; Hellman and Gitlin, 2002; Wessling-
Resnick, 2006; Steere et al. 2012).  
 
Cellular iron uptake is a receptor-mediated process and virtually all bodily cells express 
transferrin receptor 1 (TfR1) protein, which binds  and internalises the diferric transferrin 
known as a holo-transferrin complex by endocytosis (Aisen, 2004; Hentze et al. 2004). 
 
When the body’s demand for iron supply has been met, excess iron is stored in a number of 
protein stores. This includes ferritin protein composed of 24-subunits of heavy (H) and light 
(L) chains. This globular protein has the capacity to store up to 4 500 iron atoms (Harrison 
and Arosio, 1996; Arosio et al. 2009). Approximately 20% of  absorbed iron is stored in 
ferritin protein in a non-toxic form (Harrison and Arosio, 1996; Cairo et al. 2006). The H- (21 
kDA) and L (19 kDA) subunits differ metabolically and functionally, which allows ferritin to be 
tissue specific (Harrison and Arosio, 1996; Hentze et al. 2004). The former, has a high 
capacity to take up and make iron readily available for cellular use, and is located in iron 
requiring cells. The L- subunit retains iron for prolonged periods and hence is found in iron 
storing tissues (Harrison and Arosio, 1996; Hentze et al. 2004). Apart from its function as 
storage protein, ferritin has antioxidant capability to counteract iron toxicity in the body (Torti 
and Torti, 2002; Hintze and Theil, 2005). Storage proteins such as haemoglobin and 
myoglobin consist of a heme structure that allows storage of up to 70% of absorbed iron 
(Zhang and Enns, 2009). Storage sites include the bone marrow, liver and spleen (Green et 
al. 1968; Cairo et al. 2006). Macrophages recycle approximately 0.66 % iron daily from 
damaged red blood cells (Finch et al. 1970; Cairo et al. 2006). 
 
Ferritin serves as a major intracellular iron storage protein (450 kDA) that is found in virtually 
all cell types and stores iron atoms that are released in a very controlled manner depending 
on the body’s demand (Harrison and Arosio, 1996). Apart from its storage function, ferritin 
also serves as body’s natural buffering system against both iron deficiency and overload, by 
keeping iron soluble and in a non-toxic form (Torti and Torti, 2002; Hintze and Theil, 2005). 
In clinical practice serum ferritin concentrations are used for the assessment of iron status, 
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with lower levels (SF ≤ 20 µg/l) indicating iron store depletion while elevated levels (women: 
SF > 200 µg/l, men: SF > 300 µg/l) may indicate iron overload (Liu et al. 2003; Guggenbughl 
et al. 2011). Increased iron stores are associated with increased iron absorption (Cairo and 
Pietrangelo, 2000; Hentze et al. 2004; Geissler and Singh, 2011).  
 
Iron regulation is influenced by several inflammatory conditions (Torti and Torti, 2002; 
Hentze et al. 2010) involving regulatory genes encoding proteins that facilitate the 
expression of hepcidin, a 25-amino acid peptide known as the central iron regulator (Lee, 
2009; Ganz, 2011; Ganz and Nemeth, 2012). TMPRSS6 and HFE serve as the negative and 
positive modulators for hepcidin expression, respectively (Pietrangelo, 2002; Ramsay et al. 
2009; Ganz, 2011; Ganz and Nemeth, 2012). Down regulation of hepcidin expression by 
TMPRSS6, suppresses its production to increase ferroportin activity with a subsequent 
increase in iron uptake (Du et al. 2008; Ramsay et al. 2009; Ganz, 2011). This is achieved 
by proteolytic activity of TMPRSS6 to cleave hemojuvelin, a key regulator protein in the 
hepcidin transcription pathway that regulates hepcidin release via bone morphogenetic 
protein (BMP) (Barnett et al. 2006; Ramsay et al. 2009).  
 
A primary function of hepcidin is to protect against iron overload and its deleterious 
consequences. This is accomplished by binding to the sole iron exporter protein ferroportin, 
initiating its cellular internalisation and subsequent degradation, resulting in inhibited 
absorption of iron from duodenal enterocytes as well as decreased release of iron from 
macrophages into the bloodstream for erythropoiesis (Nemeth et al. 2004; Ganz, 2011). 
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Regulation of the iron absorption pathway by hepcidin and ferroportin interaction is 
illustrated in Figure1.1 
 
 
Figure 1.1. Hepcidin interaction with ferroportin controls the main iron flow into plasma. . 
[Used with the permission of Dr. Ganz from Ganz, 2011] 
 
 
1.6.3. Iron-related disorders 
The two most commonly reported iron-related disorders of opposite phenotypes are  
hereditary hemochromatosis (HH) and iron deficiency anaemia (IDA) (Morse et al. 1999; 
Leiu et al. 2001; McLaren et al. 2010).  
 
Iron accumulation is the causal factor for HH, which manifests as a wide spectrum of 
diseases including liver disease, diabetes mellitus and skin hyperpigmentation. Conversely, 
several non-genetic factors  predispose towards iron deficiency, including frequent blood 
loss, low body weight, insufficient dietary intake, age and gender (Andrews et al. 1999; 
Andrews, 2000; Melis et al. 2008). The iron content in the body differs by gender with  higher 
amounts in adult men (4.0 g) than women (3.5 g), which could mainly be due to frequent 
blood loss through menses in  females (Andrews et al. 1999; Geissler and Singh, 2011).  
 
1.6.3.1. Iron deposition in the brain versus iron deficiency 
In addition to the use of MRI in the diagnostic work-up of MS patients, specialised MRI 
sequences used exclusively for research purposes  provides an iron tracking tool to evaluate 
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the pathogenesis of MS (Bakshi et al. 2008; Khalil et al. 2011). In the gray and white matter 
of the human brain parenchyma, this specialised MRI technique is used to detect  iron  which 
is stored within ferritin in the basal glangia, globus pallidus, red nucleus and substantia nigra 
(Bagnato et al. 2011, 2013). These MRI sequences can also reveal the presence of insoluble 
iron deposits such as hemosiderin in MS lesions derived from microbleeds as well as 
hemoglobin in blood vessels (Rouault, 2013).  
 
Insoluble iron deposits identified on MRI have been documented as an iron accumulation in 
the brains of patients with MS, and reported as a potential contributing risk factor in the 
disease pathogenesis through oxidative stress (LeVine et al. 2013). However, this ‘excess 
iron’ hypothesis should be revisited before considering iron chelation therapy for all patients 
with MS (LeVine et al. 2013), as the effect of iron deficiency has been a subject of interest in 
MS as well, where lower concentrations in a subset of patients have been strongly 
suspected to worsen disease symptoms (van Rensburg et al. 2006). The assumption that 
brain iron overload detected by MRI techniques is a reflection of abnormal iron accumulation 
in neurons (Weinreb et al. 2010), has led to chelation therapies in diseases such as 
Friedreich’s and Parkinson’s disease (Boddaert et al. 2007; Sian-Hulsmann et al. 2011). This 
assumption however, may not be correct for all neurodegenerative diseases and has been 
questioned in a most recent report (Rouault, 2013). 
 
A possible mode of iron accumulation in the brain has previously been proposed that “the 
pathology associated with iron accumulations may result from functional iron deficiency in 
some disease” (Rouault and Cooperman, 2006). Whether this is the case in MS requires 
further investigation.  
 
Iron may accumulate in certain brain regions such as the globus pallidus, putamen, 
substantia nigra and caudate nucleus (Bradbury, 1997). These regions contain tyrosine 
hydroxylase, which requires iron for optimum function and is involved with dopamine 
production. Its enzymatic activity is vulnerable to iron deficiency which leads to impaired 
motor co-ordination (Beard et al. 2002; Levenson et al. 2004; Frantom et al. 2006). In the 
brain, iron exists in several forms such as protein-bound, non-heme and ferric (Fe3+), which 
are non-reactive (Koeppen, 1995). Brain cells requiring a constant supply of iron include 
oligodendrocytes, neurons, microglia and astrocytes, which have distinct metabolic features. 
Sufficient iron supply to these cells is limited by the blood BBB and blood-CFS barrier in the 
CNS (Bradbury, 1997; Ballabh et al. 2004). Oligodendrocytes are the principal cells staining 
for iron in the brain under normal conditions (Todorich et al. 2009) and are known as the 
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factory for production of myelin proteins and lipids that are essential for nerve function 
(LeVine and Chakrabarty, 2004; Van Horssen et al. 2011). The abnormality of iron 
metabolism in oligodendrocytes has been associated with reduced myelin production 
(Todorich et al. 2009) and subsequent axonal damage/loss (Trapp et al. 1999; Bruck, 2005; 
Taylor et al. 2010).   
 
Myelin production and maintenance requires continuous delivery of iron to oligodendrocytes, 
a mechanism dependent on the availability of functional iron through regulation by transferrin 
and ferritin (Abo-Krysha and Rashed, 2008; Todorich et al. 2009). Of concern is that 
increased iron stores have been detected in MS lesions, including macrophages, myelin and 
oligodendrocytes (Toshdiwal and Zarling, 1992; Barnett et al. 2006; Gemmati et al 2012). In 
particular, H-Ferritin has been identified as major iron source with readily deliverable iron to 
oligodendrocytes (Todorich et al. 2011), whereas iron in the L-Ferritin molecule is stored for 
prolonged period, and may be reflected as excess when detected by MRI (Hentze et al. 
2004). When L-Ferritin that is unavailable iron for cell use is detected on MRI, this may mean 
that sequestered iron deposits contain insoluble iron that is not bioavailable to 
oligodendrocytes, resulting in functional iron deficiency states (Rouault and Cooperman, 
2006; van Rensburg and van Toorn 2010; van Rensburg et al. 2012). Similarly, iron deposits 
could reflect the iron contained within erythrocyte haemoglobin, deposited due to 
microbleeds as a consequence of inflammation, blocked venules and damaged endothelial 
cells. When the trapped red blood cells are disintegrated, haemoglobin undergoes 
precipitation as insoluble hemosiderin (Rouault, 2013).  
 
 
1.6.3.2. Genetic factors and iron status: TMPRSS6 and HFE 
Low penetrance mutations (also referred to as functional SNPs) in the TMPRSS6 and HFE 
genes have been implicated in the pathogenesis of iron-related as well as immune-mediated 
disorders (Cairo et al. 2006; Milet et al. 2007; Benyamin et al. 2009; An et al. 2012).  
 
More than 40 polymorphisms in the TMPRSS6 gene have been identified to date; of these 
the relatively common TMPRSS6 A736V SNP (rs855791, c.2207 C>T) located in the serine 
protease domain of the TMPRSS6 gene has been strongly associated with increased risk for 
developing iron deficiency in the general population (Finberg et al. 2008; Guillem et al. 2008; 
Melis et al. 2008). This non-synonymous genetic variant causes a nucleotide substitution of 
C to T on chromosome 22, at nucleotide position 2207, within the coding region of exon 17 
(Finberg, 2008; Ramsay et al. 2009; An et al. 2012).  In the presence of the TMPRSS6 
Stellenbosch University  http://scholar.sun.ac.za
18 
Chapter 1: Literature Review 
A736V SNP, hepcidin expression is upregulated and leads to raised hepcidin 
concentrations, which in turn inhibits intestinal iron absorption and macrophage release 
(Benyamin et al. 2009; Tranglia et al. 2011). In particular, the TMPRSS6 A736V T-allele has 
been significantly associated with a reduction in iron parameters such as serum iron, ferritin 
and transferrin saturation (An et al. 2012; Gan et al. 2012).  
 
Conversely, low-penetrance mutations in the HFE gene have been associated with 
hereditary iron overload (hemochromatosis). This includes the most extensively studied HFE 
C282Y mutation (rs1800562, c.845G>A) causing a cysteine to tyrosine change at amino 
acid position 282, and HFE H63D (rs1799945, c.187C>G) caused by a histidine to aspartate 
amino acid substitution at position 63 (Feder et al. 1996; McLaren et al. 2010).  These 
mutations result in a defective HFE protein which down-regulates hepcidin expression, with 
subsequent increased iron absorption causing iron overload observed in patients with HH 
(Feder et al. 1996; Nemeth and Ganz, 2006; Pietrangelo, 2007). The effect of HFE C282Y 
accounts for nearly 85% of hemochromatosis cases, where homozygosity for the risk-
associated A-allele is associated with elevated transferrin saturation and ferritin levels, while 
elevated transferrin saturation levels in heterozygotes (GA) is but rarely accompanied by a 
clinically significant increase in body iron stores (McLaren et al. 2010; McLaren et al. 2011). 
Compound heterozygous HFE C282Y/H63D has been associated with elevated iron stores, 
while a less significant effect is observed in the absence of the HFE C282Y (McLaren et al. 
2010, 2011).  
 
Iron overload 
Genetic variations underlying iron overload have been studied extensively in MS patients 
from different population groups. Gemmati et al. (2012) reported an association between 
disability progression rates and the low-penetrance C282Y mutation in the iron-overload 
gene HFE in MS subjects, but serum iron parameters were not determined to support their 
findings. Comparably, Ramagopalan et al. (2008) found no such gene effect on clinical 
outcome in MS. Notably, Kotze et al. (2006) was the first to report that South African MS 
patients homozygous for HFE C282Y lack clinical manifestation of haemochromatosis, 
leading to the hypothesis that the effect of HFE may be masked by other genetic variant(s) 
with an opposite effect on iron metabolism. These and similar discrepancies in the literature 
have led to the development of a pathology-supported genetic testing (PSGT) strategy for 
complex, multifactorial conditions including those involving iron dysregulation (Kotze et al. 
2009). This test concept requires that the detection of a low-penetrance mutation such as 
HFE C282Y is correlated with relevant biochemical parameters where possible as the 
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genetics alone is not sufficient to explain the phenotypic expression of the gene known to be 
influenced by the environment. PSGT is focused on the development of diagnostic and 
therapeutic algorithms (Kotze et al. 2013), which may serve to identify genetic sub-groups of 
MS patients requiring different treatment strategies (van Rensburg et al. 2012). Due to the 
inter-individual variability of iron status known to be dependent upon multiple genetic and 
environmental influences, it seems possible that an individualized approach to correction of 
deranged iron metabolism in MS patients might be therapeutically beneficial. This realisation 
led to the identification of a subgroup of iron-deficient MS adult patients and children who 
benefited clinically from a systematic approach and development of a tailored management 
plan incorporating controlled iron supplementation to target iron deficiency (Rooney et al. 
1999, van Rensburg et al. 2006; van Toorn et al. 2010).  
 
Iron deficiency 
Regulation of iron homeostasis is intricately related to that of the inflammatory response via 
the hepatic secretion and activity of acute phase reactants (APR) such as ferritin and the 
recently discovered antimicrobial peptide hormone hepcidin. This is in keeping with the 
growing appreciation that the liver acts as a master regulator of iron homeostasis in humans 
and other mammals (Meynard et al. 2013). We hypothesise that variation in the TMPRSS6 
gene on expression and activity of hepcidin, which is viewed as a biochemical nexus point in 
various iron metabolism pathways, may be an important mechanism underlying the 
development of iron deficiency anaemia in MS, as well as an inducer of chronic inflammation 
or immune hyper-activation characteristic of this disease. Iron deficiency may be an initial 
trigger of MS when occurring in the context of inflammation and other relevant genetic or 
environmental factors which decrease iron uptake and release (Kotze et al. 2003; de Villiers 
et al. 2006), contributing towards demyelination and reducing the remyelination capacity of 
oligodendrocytes. This is consistent with the view that genetic sub-types of MS exist that 
differs in their predisposition towards an iron deficiency phenotype (Rooney et al. 1999; van 
Rensburg et al. 2012). However, it should be emphasised that many environmental factors 
influence iron status and contribute towards inflammation by mechanisms that are either 
dependent or independent of hepcidin function. Many other genetic factors also influence 
iron homeostasis. Specifically, mutation or knockout of the TMPRSS6 gene (which up-
regulates hepcidin expression secondary to decreased TMPRSS6 activity) influences iron 
parameters such as ferritin, and may result in a severe, atypical and treatment-resistant form 
of iron deficiency anaemia (IDA); iron-refractory IDA.  
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Recent studies showed that common variation in the TMPRSS6 gene influences the 
interaction between hepcidin and iron parameters in patients without clinically evident IDA 
and modulates the risk of defective erythropoiesis in genetically susceptible individuals 
(Pichler et al. 2011; Pelusi et al. 2013).  
 
Inflammation 
Results from recent animal studies provide further evidence in support of the shared 
relationship between iron deficiency and inflammation. It was previously shown that mice 
with IDA associated with low hepcidin levels manifested a pro-inflammatory state that was 
reduced in TMPRSS6 knock-out mice in IDA associated with high hepcidin levels. However, 
factors influencing the transcriptional response associated with chronic hepcidin over-
expression resulting from inactivation of the TMPRSS6 gene remained unknown (Pagani et 
al. 2011). Riba and colleagues (2013) recently showed that inactivation of this gene results n 
down-regulation of hepatic pathways connected to the immune and inflammatory response 
related to macrophage activation and inflammatory cytokine production. The induction of 
hepatic hepcidin secretion by pro-inflammatory mediators such as Interleukin-6 (IL-6) results 
from the binding of a phosphorylated Stat3 protein to the promoter region of the hepcidin 
gene. In turn, hepcidin suppresses the transcription and expression of IL-6 in vivo (Nemeth 
et al. 2004; Maliken et al. 2011; Ganz, 2013).  
 
Iron metabolism is closely related to functioning of the immune system and it is widely 
appreciated that both increased and decreased serum iron levels predispose towards 
infection (Riba et al. 2013). For example, it is now known that many molecules encoded by 
genes associated with the major histocompatibility complex (MHC) such as HFE 
(hemochromatosis) protein influence serum levels of various iron parameters. Also, not only 
is transferrin a necessary growth factor for T lymphocytes, but cytokines released from these 
cells could reciprocally influence transferrin expression and therefore iron status (Lieu et al. 
2001). Furthermore, the solute carrier 11a1 (SLC11A1, previously NRAMP1) gene that 
encodes an iron transporter located on the lysosomal membrane of immune cells, has been 
associated with MS as it may confer either resistance to infection or promote immunity 
(Kotze et al. 2001; de Villiers et al. 2006). This finding reported for the first time in the 
genetically homogenous population of South Africa providing a restricted gene pool 
facilitating association studies, has been confirmed in some but not all subsequent studies 
(Comabella et al. 2004; Gazouli et al. 2008). Common and rare variants in the TMPRSS6 
gene have been implicated in the pathogenesis of many disorders which involve impaired 
iron and immune regulation (Benyamin et al. 2009; An et al. 2012). About 40 genetic 
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variations have been detected in this gene (De Falco et al. 2013). The most extensively 
studied TMPRSS6 A736V non-synonymous genetic variant characterised by a nucleotide 
substitution of C to T at position 2207 in exon 17 on chromosome 22, has been strongly 
associated with an increased risk of developing iron deficiency in the general population 
(Finberg, 2008; Ramsay et al. 2009; An et al. 2012). TMPRSS6 A736V is associated with 
decreased serum iron and ferritin levels, while a similar effect on transferrin saturation has 
recently been confirmed (An et al. 2012; Gan et al. 2012). However, the effect of TMPRSS6 
A736V has not been previously analysed in MS patients. 
 
 1.7. Aims 
The present study aimed to determine the individual and combined effects of TMPRSS6 
A736V and HFE C282Y on serum iron parameters in relation to lifestyle factors, age of 
disease onset and clinical outcome as assessed by the EDSS in South African MS patients. 
 
The specific objectives were as follows: 
 Comparison of the allele frequencies and genotype distribution of TMPRSS6 A736V 
(rs855791, c.2207C>T) and HFE C282Y (rs1800562, c.845G>A) between patients 
diagnosed with MS and unaffected controls. 
 Determination of the effects of clinical characteristics, lifestyle factors and genotype 
on serum iron, transferrin, transferrin saturation and ferritin levels in MS patients 
compared to population matched controls. 
 Determination of clinical outcome in relation to age of onset and degree of disability in 
MS patients. 
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2.1. RESEARCH MATERIALS  
2.1.1. Ethics Approval and Clearance 
Overall ethics approval for the project has been granted (N07/09/203 and N09/08/224) by the 
Human Research Ethics Committee of Stellenbosch University, at the Faculty of Medicine 
and Health Sciences. 
 
2.1.2. Selection of study population 
The study cohort consisted of 426 unrelated subjects: 307 Caucasian females and 100 
males, 11 Coloured (Mixed ancestry) females, 3 Asian females, 4 African females and 1 
male. All non-Caucasian individuals (Africans, Coloureds and Asians) were excluded from 
comparative analyses in order to exclude race as a confounder. Full data sets were not 
available on all study participants; therefore the sample numbers included per analysis were 
indicated where appropriate.  
 
2.1.2.1. Cases 
A total of 126 unrelated patients previously diagnosed with MS were included in the present 
study. This included 49 DNA samples of Caucasian patients from a study previously 
performed (Kotze et al. 2001), their age of MS onset (diagnosis/symptoms) was previously 
recorded but no additional information on clinical and lifestyle profiles were available. The 
EDSS scores of MS patients were determined as previously described (van Rensburg et al. 
2006). For the purpose of this study, only baseline EDSS values available for 48 MS patients 
were used. 
 
2.1.2.2. Controls  
A total of 300 unrelated controls individuals without a history or clinical presentation of 
neurological illness were identified from a secure database (access at www.gknowmix.org) of 
individuals enrolled in a chronic disease risk screening program.  
 
The Caucasian study population consisted of 121 MS patients (16 males, 105 females) and 
286 controls (84 males, 202 females), between the ages of 19 and 98 years, used in 
comparative studies. Subgroup analysis was performed in the event that a full data set was 
not available for all individuals. 
 
2.1.3. Inclusion and Exclusion Criteria 
Inclusion criteria were: patients diagnosed with definite MS by their respective neurologists, 
and informed consent provided.  
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Exclusion criteria were: individuals with other demyelinating diseases such as neuromyelitis 
optica, and informed consent for laboratory testing not provided. 
 
 
2.2. DATA CAPTURING METHODS 
The medical and lifestyle profiles of a subset of study participants (70 patients and 59 
controls) were collected through a questionnaire (Gknowmix™ nutrition questionnaire) 
available on the website (www.gknowmix.com), which contained questions on dietary intake, 
medical history (family and own), exposure to lifestyle risk factors and daily exercise 
(physical and/or daytime activity). Scores were assigned for dietary portions of several foods 
containing carbohydrate, fat (saturated/trans), folate, fruit/vegetable and fibre. Under medical 
history, the following were recorded: MS medication, age of disease diagnosis, age of first 
symptom presentation and disability status which was indicated by EDSS scores ranging 
from 0.0 to 10.0 (Kurtzke, 1983) (Appendix B). Lifestyle risk factors such as alcohol 
consumption was calculated as units and risk scores (0 to 4) were generated accordingly 
(abstain = 0, occasionally/1-2 Units = 1, week/1 -13 Units = 2, week/13-21 Units = 3 and 22 
Units or more = 4), while exposure to cigarette smoke was recorded as current smoker or 
previous (less than a year). Scores (1 to 4) were also assigned for physical activities as 
follows: none/occasionally = 1, once per week = 2, 2-3 times = 3, and a score of 4 was 
assigned for exercising 4 or more times per week. Daytime activity recorded as any day 
activity that lasted more 30 minutes including walking and occupational activities, and scored 
(1 to 3) as 1 = sedentary, 2 = moderate and a score of 3 was noted as intense day activity. 
Body mass index (BMI) which has direct correlation to the measures of body fat was here 
assessed as it marks one of the major contributing health risk factors in the general 
population. The weight categories include 18.5-24.9 kg/m2 for a normal weight, BMI below 
18.5 kg/m2 indicates underweight and overweight between 25.0- and 29.9 kg/m2, while 
obesity is categorised by BMI above 30.0 kg/m2. 
 
2.2.1. Blood status parameters analysis  
Peripheral venous blood samples were collected from all eligible subjects by a suitably 
experienced clinician according to standard practices. Serum iron, ferritin, transferrin levels 
as well as transferrin saturation were determined as previously reported (Kotze et al. 2006; 
van Rensburg et al. 2006) and results were entered into a secure database.  
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2.2.2. Research methods 
Saliva and whole blood samples were obtained from study participants with informed consent 
and DNA was extracted from saliva and whole blood for genotyping of TMPRSS6 A736V and 
HFE C282Y. 
 
2.2.3. Extraction of DNA from saliva and whole blood samples 
Genomic DNA from saliva samples were accomplished using the Oragene® –DNA/Saliva Kit 
(protocol), and extractions from whole blood was performed using the QIAGEN® QIAamp 
DNA Blood Midi Kit as described in the protocol (Spin Protocol) provided. The extraction 
procedures were as follows:  
 
2.2.3.1. DNA extraction from Saliva: Oragene® –DNA/Saliva Kit  
The Oragene® DNA/Saliva sample (viscous) was mixed in the Oragene® –DNA vial by 
inverting several times and gentle shaking for a few seconds. The sample was incubated at 
50°C in a water bath for 1 hour, in order to release adequate DNA into the solution. Under 
these conditions nucleases are permanently inactivated. After incubation, 500 µl of the 
sample was transferred to a microcentrifuge tube (1.5 ml), and a 20 µl Oragene®-DNA 
purifier (OG-L2P) solution was added and vortexed for 10 seconds. The mixed sample was 
incubated on ice for 10 minutes, in order to effectively remove the impurities. Following 
incubation, the vial was centrifuged at 13,000 rpm (15,000 X g) at room temperature (22 – 
25°C) for 10 minutes, allowing proper separation of DNA from the precipitated impurities. 
Glycogen solution (5 µl) was added into the supernatant containing DNA, which made the 
pellet more visible.  
 
A pipet tip was used to carefully transfer the supernatant into a fresh microcentrifuge tube, 
and the remaining pellet containing impurities was discarded. Then 95 – 100% ethanol 
solution (500 µl), at room temperature, was added to the supernatant and gently mixed by 
inversion 10 times. The sample was incubated at room temperature (22 – 25°C) for 10 
minutes, to allow the DNA to fully precipitate. The tube was then placed in the 
microcentrifuge in a known orientation (e.g, with the hinge portion of the cap pointing away 
from the centre of the rotor, to keep track of the DNA pellet, which was expected to be 
located at the tip of the tube below the hinge), and centrifuged at room temperature (22 – 
25°C) at 13,000 rpm (15,000 X g) for 2 minutes. 
 
The supernatant containing impurities was carefully discarded using a pipet tip without 
disturbing the DNA pellet, which was washed with 70% ethanol (250 µl) and incubated for 1 
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minute at room temperature to remove residual inhibitors. Thereafter the ethanol was 
completely removed. This was followed by the addition of a DNA buffer (100 µl) (Nuclease 
Free Water) and mixing by vortexing for at least 5 seconds, to completely dissolve the DNA 
pellet. The purified DNA samples were incubated at room temperature on a shaker overnight 
to allow complete homogenization, and were stored at 4°C for frequent use. 
 
2.2.3.2. DNA extraction from Whole Blood: QIAamp® DNA Blood Midi Kit (Spin 
Protocol) 
From each whole blood sample, 2 ml blood containing Ethylenediaminetetraacetic acid 
(EDTA) was treated with several QIAGEN solutions in order to extract and purify the DNA. 
The extractions were performed using the QIAamp DNA whole blood extraction protocol 
(QIAGEN®) as follows:  
 
The first step of cell lysis in order to release DNA from the nucleus was achieved by adding 
QIAGEN protease stock solution (200 µl) into a 15 ml centrifuge tube containing whole blood 
samples (2 ml), and vigorous shaking the contents on a vortex apparatus to increase the 
proteolysis reaction. A second lysing solution, buffer AL (2.4 ml) was added into the 
centrifuge tube mix, followed by thorough mixing by inverting the tube at least 15 times for 
adequate lysis. One extra minute of brief vortexing was added to ensure that the lysed 
solution was homogenous. The homogenous solution was incubated on a dry block (70°C) 
for 10 minutes, to increase DNA yield.  
 
After incubation and removal of the 15 ml centrifuge tube with homogenised sample from the 
dry block, 96 - 100% ethanol (2 ml) was added. The solution was thoroughly mixed by 
inverting the tube 10 X with additional vigorous shaking (vortexing). Thereafter approximately 
3 ml of the solution was transferred into the QIAamp® Midi spin column, and placed back into 
the 15 ml centrifuge tube, then centrifuged for 3 minutes at 3000 rpm (1850 x g). The filtrate 
was discarded and the remaining solution (~ 3 ml) was transferred into the QIAamp® Midi 
spin column and centrifuged at 3000 rpm (1850 x g) for 3 minutes.  
 
The QIAamp® Midi spin column was transferred into a fresh 15 ml collection tube, a volume 
(2 ml) of wash buffer AW1 was added to the column membrane, then centrifuged for 1 
minute at 5000 rpm (4500 x g). A second wash buffer AW2 (2 ml) was added to the 
QIAamp® Midi spin column, then centrifuged (5000 rpm/4500 x g) for 15 minutes, to ensure 
complete removal of the AW2 from the QIAamp® Midi spin column. The column was placed 
into a clean 15 ml collection tube, and the filtrate was discarded. The DNA was eluted from 
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the QIAamp® Midi spin column by adding 300 µl of nuclease-free water which was 
equilibrated to room temperature (22 – 25°C), directly onto the column membrane. The 
column was incubated at room temperature for 5 minutes, and then centrifuged at 5000 rpm 
(4500 x g) for 2 minutes. The eluted contents (~300 µl) were reloaded onto the QIAamp® Midi 
spin column and the previous incubation and centrifugation steps were repeated to maximize 
the DNA concentrations obtained. The DNA samples were stored at 4°C for frequent use, 
while aliquots were stored at - 20°C for long term usage.  
 
2.3. DNA QUANTIFICATION AND AMPLIFICATION 
 
2.3.1. The NanoDrop instrument 
A NanoDrop® ND-1000 Spectrophometer was used to measure the concentration and purity 
of the DNA samples. The results were subsequently captured on a connected v3.5.2 
software package. The software was switched on, and then the Nucleic Acid analysis was 
selected. The pedestal surfaces were cleaned with ethanol (70%) and double distilled water 
(dd-H2O). Upon completion the instrument was initialized by loading 2 µl of nuclease free 
water, followed by blanking (0.0 ng/µl) the instrument by loading 2 µl of RNase free water 
onto the pedestal. After blanking was completed, 2 µl DNA sample was pipetted onto the 
pedestal and measurements (DNA concentration, purity ratios) were captured and stored for 
each sample. The pedestal was cleaned between each measurement. DNA purity was 
assessed by absorbance readings at ratios of 260/280 (1.6 – 1.9) and 260/230 (> 2.0), which 
indicated the absence of proteins and RNA contaminants, respectively. All the DNA samples 
of known concentrations were diluted with nuclease free water to give a final 10 ng/µl DNA 
concentration, which was suitable for RT-PCR genotyping. 
 
2.3.2. Oligonucleotide primer design 
The polymorphisms studied included the rs855791 TMPRSS6, which is a polymorphism that 
causes a pyrimidine nucleotide base change from cytosine (C) to thymine (T) at nucleotide 
position 2207 (c. 2207 C>T), resulting in an alanine (A) to (V) valine substitution at amino 
acid position 736 (A736V). The rs1800562 HFE polymorphism which results in a purine 
nucleotide base change from guanine (G) to adenine (A) at position 845 (c. 845 G>A), leads 
to a substitution of cysteine (C) by tyrosine (Y) at amino acid position 282 (C282Y).  
Oligonucleotide primer sequences for the selected polymorphisms (TMPRSS6 c.2207C>T 
and HFE c.845 G>A) were designed using available online primer design software packages 
(Table 2.1). The genomic reference sequences were extracted from the National Center for 
Biotechnology Information (NCBI), an online database (www.ncbi.nlm.nih.gov). The primer 
Stellenbosch University  http://scholar.sun.ac.za
27 
Chapter 2: Materials and Methods 
sets were then ordered from Whitehead Scientific Pty (Ltd) and synthesised by Integrated 
DNA Technologies (IDT). Conventional PCR methodology and direct DNA sequencing were 
employed using these primers to identify genotyping controls for use in the high-throughput 
real-time PCR (RT-PCR) screening.  
 
Primers designed were specific for the selected SNPs, (rs855791 / c.2207 C>T) TMPRSS6 
A736V and (rs1800562 / c.845 G>A) HFE C282Y, using appropriate software programs 
available online.  
 NCBI database was used to retrieve SNP sequences using available reference 
numbers (rs numbers) as assigned for each SNP (www.ncbi.nlm.nih.gov). 
 Primer3Plus tool was used to design oligonucleotide primers (forward and reverse) 
flanking the SNP of interest (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/). 
 SNPCheck v3-Manchester tool was used to identify the presence of other SNPs that 
may be situated within the primers. This was done to avoid result discrepancies 
during genotyping analysis (https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck). 
 The IDT Oligoanalyzer tool was used to evaluate the primer parameters including 
primer melting temperature, GC content, hairpin structure, dimers (self/homo and 
hetero) (http://eu.idtdna.com/analyzer/applications/oligoanalyzer/). 
 
The PCR products were visualized by agarose gel electrophoresis. The unpurified PCR 
products were sent for sequencing analysis at the Central Analytical Facility of Stellenbosch 
University.  
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Table 2.1 Oligonucleotide primer sequences designed for conventional PCR methodology 
Gene SNP ID 
SNP 
position 
Primer Oligonucleotide Sequence (5' - 3') 
G-C 
Content 
(%) 
Tm 
(°C) 
TA 
(°C) 
Amplicon Size 
(bp) 
         
TMPRSS6 rs855791 
c.2207 
C>T 
V736A 
Forward TGA CCT CAG GTG TTC CGT C 57.8 56.7 
59 534 
Reverse AGG CTT CAG CAG GCT GAT G 57.8 57.8 
         
HFE rs1800562 
c.845 G>A 
C282Y 
Forward TGG CAA GGG TAA ACA GAT CC 50.0 54.8 
56 396 
Reverse TAC CTC CTC AGG CAC TCC TC 60.0 57.9 
   Abbreviations: SNP, single nucleotide polymorphism; ID, identification; Tm, melting temperature; TA, annealing temperature; bp, base pairs; 
TMPRSS6, transmembrane protease, serine-6 gene; HFE, hemochromatosis gene. 
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2.3.3. DNA amplification by conventional PCR methodology 
Amplification of the targeted genetic variations in the TMPRSS6 and HFE genes enabled the 
identification of the respective genotypes through conventional DNA sequencing. 
Conventional PCR methodology was performed using a Promega GoTaq® Flexi DNA 
Polymerase PCR kit, for amplification of the targeted sequence region of the TMPRSS6 gene 
on chromosome 22 flanking the c2207 C>T (rs855791) polymorphism, and that of the HFE 
gene on chromosome 6 flanking the HFE c.845 G>A (rs1800562) polymorphism.  
 
Applied Biosystems® thermal cyclers (2700 and 9700) were used for targeted regions 
amplification. The reaction mixture contained a colourless GoTaq® Flexi Buffer (1 X) 
(Promega), MgCl2 (1.5 mM) (Promega), Forward and Reverse primers (0.24 µM each) (IDT), 
GoTaq® DNA polymerase (1.25 U) (Promega), template DNA (100 ng), dNTPs {dATP, dTTP, 
dGTP and dCTP (0.2 mM each)} (Applied Biosystems) and nuclease-free water. The 
amplification was performed on the Applied Biosystems® GeneAmp® PCR System 2700 
thermal cycler, in 25 µl reactions under specific thermal cycle conditions for the individual 
genes TMPRSS6 (Table 2.2) and HFE (Table 2.3). 
 
 
Table 2.2 Thermal Cycling conditions of conventional PCR for TMPRSS6 c.2207C>T 
Steps Cycles (X) Temperature (°C) Time (minute) 
Initial Denaturation 1 95 02:00 
Denaturation 
28 
95 00:30 
Annealing 59 00:30 
Extention 72 00:30 
Final Extention 1 72 05:00 
Cooling 1 22 01:00 
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Table 2.3 Thermal Cycling conditions of conventional PCR for HFE C282Y  
Steps Cycles (X) Temperature (°C) Time (minute) 
Initial Denaturation 1 94 05:00 
Denaturation 
35 
94 00:30 
Annealing 56 00:30 
Extention 72 02:00 
Final Extention 1 72 10:00 
Cooling 1 22 01:00 
 
Conventional PCR amplification of targeted sequence regions flanking the TMPRSS6 A736V 
and HFE C282Y polymorphisms, yielded different sized amplicon fragments that were 
separated by gel electrophoresis on a 2 % (w/v) agarose gel and visualized by staining with 
ethidium bromide. 
 
2.3.4. Gel Electrophoresis analysis 
The success of the PCR amplification reactions was evaluated by gel electrophoresis. PCR 
products were separated on a 2 % (w/v) agarose gel to ensure that the expected fragment 
sizes were obtained as compared with a size marker loaded on the same gel.  
 
Two grams (g) of agarose powder (Seakem® LE agarose) was weighed and added into a 100 
ml of 1 X TBE (90 mM Tris-HCl (pH 8.0), 90 mM Boric acid, 1mM EDTA (pH 8.0) and ddH2O) 
buffer solution in an Erlenmeyer flask. The mixture-containing flask was placed in a 
microwave for 3 minutes on highest setting, and then equilibrated at room temperature (22 – 
25°C) for 10 to 15 minutes. The gel was poured into a casting tray with a comb inserted to 
make wells on the gel, and was allowed to solidify at room temperature for 30 minutes. The 
comb was carefully removed from a solid gel, and the casting tray was transferred to the 
electrophoresis tank containing running buffer (700 ml 1 X TBE buffer and 70 µl 0.01 % (v/v) 
Ethidium Bromide). 
 
Each labelled well was loaded with a mixture of 5 µl of loading dye (Ficoll Orange G) and 
either 3 µl of PCR product or 3 µl of the 100bp DNA Ladder (Promega®). The electrophoresis 
was performed at 100V for 45 minutes to allow separation of the amplicons. The gel was 
visualised under ultra-violet light using a transilluminator (GibcoBRL Life Technologies, 
California, USA).   
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2.3.5. Conventional DNA sequencing analysis 
The unpurified PCR products obtained for the TMPRSS6 c.2207 C>T (rs855791) and HFE 
c.845 G>A (rs1800562) polymorphisms were sent to the Central Analytical Facility of 
Stellenbosch University (CAFSU), for Post PCR Clean-Up and Direct DNA Sequencing. The 
automated DNA sequencing analyses enabled identification of three genotypes 
(homozygous Wild Type, heterozygous and homozygous Mutant) for each SNP (Table 2.4). 
The DNA sequencing results from CAFSU were analysed using the FinchTV Version 1.4.0 
software (www.geospiza.com), which generated the electropherograms depicting nucleotide 
sequences of each gene (TMPRSS6 and HFE). The four ddNTP (ddATP, ddCTP, ddGTP 
and ddTTP) molecules are distinguished by four distinct fluorescence colours and are 
represented as colour peaks on the electropherogram. The position of the SNP was detected 
by comparing these nucleotide sequences to the gene reference sequences obtained from 
the NCBI database (www.ncbi.nlm.nih.gov).  
 
Table 2.4 Identified genotypes by conventional DNA sequencing 
Genotypes TMPRSS6 c.2207 C>T 
(A736V) 
HFE c.845 G>A 
(C282Y) 
   
Homozygous Wild Type CC GG 
   
Heterozygous CT  GA 
   
Homozygous Mutant  TT AA 
   
Abbreviations: SNP, single nucleotide polymorphism; TMPRSS6, transmembrane protease, 
serine-6 gene; HFE, hemochromatosis gene 
 
 
2.4. GENOTYPING ANALYSIS  
Control samples for TMPRSS6 A736V and HFE C282Y were identified via DNA sequencing 
of internal control samples (K1, K2, K3, K4 and K6), for the identification of the wild-type, 
heterozygous and homozygous genotypes. These were included as controls in subsequent 
genotyping of 426 DNA samples from study participants: 126 MS patients (121 Caucasian, 5 
Coloured) and 300 controls (286 Caucasian, 6 Coloured, 5 African, 3 Asians).  
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2.4.1. RT-PCR amplification 
High-throughput RT-PCR methodology was applied for genotyping using Applied Biosystems 
(ABI™) TaqMan® SNP Genotyping assays for TMPRSS6 A736V and HFE C282Y SNPs. 
This was performed on the ABI™ 7900HT Fast Real-Time PCR System using assays 
TMPRSS6 rs855791 C___3289902_10 and HFE rs1800562 C___1085595_10. These 
assays are standardized and consist of allele-specific primers and TaqMan® Minor Groove 
Binder (MGB) probes (dye-labelled FAM™ and VIC® denoting either mutant or wild type 
alleles) for the detection of the SNP of interest. Sterile double-diluted SABAX water was used 
to perform a 20 X dilution series on the 40 X TaqMan® SNP Genotyping assays, as required 
for the RT-PCR instrument used for end-point genotyping by allelic discrimination. 
 
Genotyping of DNA samples was performed on an ABI™ 7900HT Fast RT-PCR system 
using ABI™ TaqMan® SNP Genotyping assays. The reaction mixture contained: 2.75 µl of 
SABAX water (nuclease free water), 5 µl of TaqMan® genomic master mix, 0,25 µl of 20 X 
TaqMan® SNP Genotyping assay and 4 µl of 10ng/ µl template specific DNA made up to a 12 
µl final reaction volume. The thermal cycling conditions for RT-PCR amplification runs is 
summarised in table 2.5. 
 
Table 2.5 Thermal Cycling conditions of RT-PCR  
Steps Cycles (X) Temperature (°C) Time (minute) 
Initial Denaturation 1 95 10:00 
Denaturation 
40 
92 00:15 
Annealing/Extention 60 01:00 
 
 
2.5. Statistical analysis 
Genotype distribution and allele frequencies of TMPRSS6 A736V and HFE C282Y were 
evaluated from allele counts and Hardy-Weinberg equilibrium was tested using an online 
Court-lab Hardy Weinberg calculator (Michael H. 2005-2008). Analysis of variance (ANOVA) 
was used to determine the individual and combined effects of TMPRSS6 A736V and HFE 
C282Y on clinical outcomes (age of symptom onset, age of diagnosis and EDSS score) as 
well as iron parameters (serum iron, ferritin, transferrin and transferrin saturation). Prior to 
performing genotype-phenotype association studies, possible demographic factors and 
lifestyle habits were identified as potential confounders that were subsequently adjusted for. 
These included age, sex, BMI, dietary red meat intake, alcohol intake, smoking status and 
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physical activity. A log transformation model was used to correct normality for non-symmetric 
distributions as was the case for serum ferritin. Fisher least significant difference (LSD) post-
hoc tests were performed to determine possible differential effects of TMPRSS6 A736V and 
HFE C282Y, single or combined, on serum iron parameters and clinical outcome. 
Significance threshold was set at p ≤ 0.05. 
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3.1. Study population 
The Caucasian study population consisted of 121 MS patients (16 males, 105 females) and 
286 controls (84 males, 202 females) between the ages of 19 and 98 years. All non-
Caucasian individuals (5 MS patients and 14 controls) were excluded in comparative studies 
to exclude race as possible confounder. Analysis of the TMPRSS6 rs855791 (c.2207C>T, 
A736V) and HFE rs1800562 (c.845G>A, C282Y) polymorphisms (Table 3.1) was conducted 
with conventional PCR and direct DNA sequencing (as the gold standard) for the 
identification of the respective wild-type, heterozygous and homozygous genotypes. 
 
Table 3.1 Low-penetrance mutations studied in relation to iron metabolism  
Gene Genetic Variations Metabolic Associations 
   
TMPRSS6 rs855791, c.2207  
C>T, (A736V) 
Iron deficiency anaemia 
   
HFE 
rs1800562, c.845 
G>A, (C282Y) 
 
Iron overload, Hereditary hemochromatosis 
 
Abbreviations: TMPRSS6, transmembrane protease, serine-6 gene; HFE, 
hemochromatosis gene 
 
3.1.1. Optimisation of high throughput genotyping  
The accuracy of the RT-PCR screening method used was verified by comparing pre-
sequenced internal control samples and including them as positive controls during each 
allelic specific PCR run to corroborate the results generated during the screening process. In 
the present study, the initial optimisation / assay standardisation phase involved genotyping 
of 300 DNA samples from unrelated controls, which was performed by a high-throughput RT-
PCR genotyping methodology as described in sections 2.4.1 and 2.3.5. The standardised 
RT-PCR assays for each selected SNP were used for genotyping of 126 MS patients whose 
genotyping results were subsequently compared with that of the control subjects. 
 
3.1.2. Conventional PCR and gel electrophoresis  
The DNA samples were successfully amplified by conventional PCR and yielded PCR 
products as visualized on an agarose gel (Fig.3.1 A-B) using the techniques described in 
sections 2.3.3 and 2.3.4. Amplification of the internal control samples yielded the expected 
DNA fragment sizes as compared against a 100 bp DNA ladder (lane 1), for the TMPRSS6 
Stellenbosch University  http://scholar.sun.ac.za
35 
Chapter 3:Results  
(534 bp: lane 2-5) and HFE (396 bp: lane 2-4) gene sequences. No amplification occurred 
with the non-template control (NTC) samples that did not contain any DNA, shown by the 
blank lanes which confirm the absence of contamination in each PCR reaction.  
 
Figure 3.1 illustrates separation of PCR amplicons (534 bp) synthesised with the TMPRSS6 
(A736V) primer set visualized with 0.0001 % (v/v) Ethidium Bromide solution. Lane 1 
contains a 100 bp DNA ladder with the amplicons in lane 2 through 5 and NTC in lane 6 
indicating the absence of contamination. PCR amplicons (396 bp) synthesised with the HFE 
(C282Y) primer set is visualized with 0.0001 % (v/v) Ethidium Bromide solution. Lane 1 
contains a 100 bp DNA ladder, with the amplicons in lane 2 through 4 and NTC in lane 5 
indicating the absence of contamination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. A) A 2 % (w/v) agarose gel depicting PCR amplicons synthesised with 
TMPRSS6 (A736V) primer set. B) A 2 % (w/v) agarose gel depicting PCR amplicons 
synthesised with the HFE (C282Y) primer set.   
 
 
3.1.3. Genotype identification by Direct DNA sequencing 
The PCR products were sequenced to detect the presence of the TMPRSS6 A736V and 
HFE C282Y SNPs, and this was achieved by direct DNA sequencing (section 2.3.5). In 
Figure 3.2 A-C through 3.3 A-C, the analysed data is presented as electropherograms 
showing the position of the SNP.  
534 bp 
100 bp 
300 bp 
 600 bp 
396 bp 
100 bp 
200 bp 
500 bp 
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3.1.3.1. TMPRSS6 A736V 
DNA sequencing reactions confirmed the presence of TMPRSS6 A736V through the 
identification of three genotypic states; Wild-Type (mutation not detected), homozygous and 
heterozygous genotypes. The Wild-Type (Fig.3.2 A), Homozygous (Fig.3.2 B) and 
heterozygous (Fig.3.2 C) genotypes for TMPRSS6 A736V, were identified from the forward 
(sense) and reverse (anti-sense) sequencing reactions. The SNP position is shown by 
electropherograms and is highlighted in light blue colour, Fig.3.2 A–C, which gives a 
representation of some of the results.  
 
Figure 3.2 shows the electropherogram generated from the TMPRSS6 (A736V) primer set. 
The SNP position indicated by C (blue) represents a Wild-Type (CC) genotype. The 
electropherogram generated from the TMPRSS6 (A736V) primer set shows the SNP position 
indicated by T (blue), representing a homozygous (TT) genotype. The electropherogram 
generated from the TMPRSS6 (A736V) primer set for the SNP position indicated by Y (blue) 
represents a heterozygous (CT) genotype.  
 
3.2. A) Electropherogram depicting the reverse (anti-sense) sequencing reaction of PCR amplicon of 
TMPRSS6 (A736V) primer set yielded a Wild-Type (CC) genotype. B) Electropherogram depicting the 
forward (sense) sequencing reaction of PCR amplicon of TMPRSS6 (A736V) primer set yielded 
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homozygous (TT) genotype.  C) Electropherogram depicting the forward (sense) sequencing reaction 
of PCR amplicon of TMPRSS6 (A736V) primer set yielded heterozygous (CT) genotype.  
 
3.1.3.2. HFE C282Y 
The DNA sequencing reactions confirmed the presence of HFE C282Y through the 
identification of three genotypic states; Wild Type (mutation not detected), homozygous and 
heterozygous genotypes. The Wild Type (Fig.3.3 A), Homozygous (Fig.3.3 B) and 
heterozygous (Fig.3.3 C) genotypes for HFE C282Y amplicon, were identified from the 
forward (sense) and reverse (anti-sense) sequencing reactions. The SNP position is shown 
by electropherograms, and is highlighted in light blue colour. 
 
Figure 3.3 shows the electropherogram generated from the HFE (C282Y) primer set. The 
SNP position is indicated by G (blue) representing the Wild Type (GG) genotype. The 
electropherogram generated from the HFE (C282Y) primer set for the SNP position indicated 
by A (blue), represents the homozygous (AA) genotype. The electropherogram generated 
from the HFE (C282Y) primer set for the SNP position indicated by R (blue) represents a 
heterozygous (GA) genotype.  
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Figure 3.3. A) Electropherogram depicting the forward (sense) sequencing reaction of PCR amplicon 
of HFE (C282Y) primer set, yielded a Wild Type (GG) genotype. B) Electropherogram depicting the 
forward (sense) sequencing reaction of PCR amplicon of HFE (C282Y) primer set, yielded a 
homozygous (AA) genotype. C) Electropherogram depicting the forward (sense) sequencing reaction 
of PCR amplicon of HFE (C282Y) primer set, yielded a heterozygous (GA) genotype.  
 
3.1.4. High-throughput RT-PCR  
Genotyping of 426 DNA samples (126 MS patients and 300 controls) was performed by a 
high-throughput RT-PCR assay on the ABI™ 7900HT instrument, using the TaqMan® SNP 
genotyping assays for the two selected SNPs as described in section 2.4.1. Allele specific 
RT-PCR amplification was successfully achieved for both the TMPRSS6 A736V and HFE 
C282Y SNPs, with discriminated allele pairs in three different combinations of wild-type (non-
mutant) and carrier (mutant) forming groups according to fluorescence colours (blue, green 
and red) as depicted in the amplification and allelic discrimination plots (Fig.3.4 A-B and 3.5 
A-B). 
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Figures 3.4 A and B show amplification and allelic discrimination plots depicting successful genotyping reactions and genotype clustering of 
TMPRSS6 A736V.  
 
                                                        A                                                                                                           B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: A) Amplification plot obtained using the ABI™ TaqMan® assay for TMPRSS6 (A736V). (B) Representation of an allelic discrimination analysis 
using ABI™ TaqMan® assay for TMPRSS6 (A736V) [Allele Y (C_3209902_10-G) vs Allele X (C_3209902_10-A)]. Blue dots = Wild type (CC), red dots = 
homozygous (TT), green dots = heterozygous, black dots = NTCs (controls for the assay). 
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Figures 3.5 A and B show amplification and allelic discrimination plots depicting successful genotyping reactions and genotype clustering of 
HFE C282Y. 
 
                                                       A                                                                                                           B 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.5: A) Amplification plot obtained using the ABI™ TaqMan® assay for HFE (C282Y). B) Representation of an allelic discrimination analysis using 
ABI™ TaqMan® assay for HFE (C282Y) [Allele Y (C_1005595_10-A) vs Allele X (C_1005595_10-G)]. Blue dots = homozygous (AA), red dots = Wild-type 
(GG), green dots = heterozygous (AG), black dots = NTCs (controls for the assay). 
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3.2. Genotype distribution and allele frequency comparison of TMPRSS6 A736V and 
HFE C282Y SNP between MS patients and controls from the same population group  
 
Genotype distribution of TMPRSS6 A736V as observed in 407 MS patients and controls was 
achieved by ABI™ TaqMan® TMPRSS6 rs855791 genotyping assay is shown in Figure 3.6. 
No significant difference in TMPRSS6 A736V distribution was found between MS and control 
population (p = 0.419).   
 
 
 
 
Figure 3.6. Comparison of genotype distribution of TMPRSS6 A736V between 121 MS 
patients and 286 controls: genotypes present as Wild Type (CC), heterozygous (CT) and 
homozygous (TT).  
 
 
  
PATIENTS CONTROLS 
n = 33 
n = 65   
n = 23                            
   n = 96 
n = 136 
n = 54 
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Determination of the genotype distribution of HFE C282Y observed in 306 MS patients and 
controls was achieved by ABI™ TaqMan® HFE rs1800562 genotyping, shown in Fig. 3.7. 
We found no significant difference in the HFE C282Y genotype distribution between MS 
patients and the control group (p = 0.706). Due to the small number of HFE homozygotes 
(AA) these individuals (2 patients and 3 controls) were excluded from subsequent genotype-
phenotype association studies. This was considered appropriate due to the autosomal 
recessive inheritance pattern of the type of haemochromatosis characterised by this 
genotype, while the effect on iron loading in heterozygotes depends on gene-gene and gene-
environment interaction similar the low-penetrance TMPRSS6 A736V mutation/SNP.  
 
 
 
Figure 3.7. Comparison of genotype distribution of HFE c.845 G>A (C282Y) between 120 
MS patients and 186 control subjects: genotypes present as Wild Type (GG), heterozygous 
(GA) homozygous (AA). 
 
 
  PATIENTS        CONTROLS 
n = 97 
n = 21 
n = 2 
n = 157 
n = 26 
n = 3 
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In both the patient and control groups the polymorphisms analysed were in Hardy-Weinberg 
equilibrium (HWE): TMPRSS6 c.2207 C>T (HWE: p = 0.368 in MS patients and p = 0.635 in 
controls) and HFE c.845 G>A (HWE: p = 0.494 in MS patients and p = 0.129 in controls). 
Genotype distribution did not differ significantly between MS patients and controls (Fig. 3.6 
and 3.7), with p-values of 0.419 and 0.706 for TMPRSS6 c.2207 C>T and HFE c.845 G>A, 
respectively. Notably, genotyping results for the TMPRSS6 A736V are shown here for the 
first time in a South African population - the distribution of the risk-associated T-allele was 45 
% in MS patients and 43 % in controls. Similarly, distribution of the HFE c.845 G>A risk-
associated A-allele was not significantly different between MS patients and controls, with 
frequencies of 10 % and 9 %, respectively. 
 
 
3.3. Genotype-phenotype association 
 
Clinical characteristics 
The baseline clinical and biochemical characteristics of 121 Caucasian MS patients and 286 
Caucasian controls are compared in Table 3.2. Due to an increased prevalence of both MS 
and iron deficiency in females, a gender-based comparison was also performed in both 
groups, which confirmed a significant difference in serum iron parameters between males 
and females. A significant difference in mean age was noted between MS patients and 
controls (p=0.002). Therefore, comparison of the biochemical parameters were repeated in 
59 controls within the same age group as the MS patients to exclude the possibility that any 
differences detected could be ascribed to older age of the control group. MS patients were 
more likely to be current smokers (p=0.04) and ate less red meat as part of their diet 
(p=0.03) when compared to controls. Heritability of MS was confirmed by a significantly 
higher family history of this condition in MS patients compared with controls (p=0.04). 
 
Table 3.2. Baseline clinical and biochemical characteristics of MS patients compared to 
controls including gender-based comparison in both study groups. The number of samples 
analysed in each group is provided in brackets. 
 
MS Patients (n=121) 
Means 
Controls (n=286) 
Means 
Gender 
Female 
(105) 
Male (16) 
Gender 
comparis
on (P-
value) 
Female 
(202) 
Male (84) 
Gender 
comparis
on (P-
value) 
Patients 
vs 
controls 
(P-value) 
Age (years) 44.95 44.00 0.85 53.53 52.24  0.59 0.002 
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MS Patients (n=121) 
Means 
Controls (n=286) 
Means 
Gender 
Female 
(105) 
Male (16) 
Gender 
comparis
on (P-
value) 
Female 
(202) 
Male (84) 
Gender 
comparis
on (P-
value) 
Patients 
vs 
controls 
(P-value) 
(104)  (16) (201) (83) 
Family history of MS (yes) 4 0  1 1  0.04 
Clinical indicators        
Body Mass Index (kg/m
2
) 25.65(57) 26.06 (5) 0.88 26.74(196) 26.44 (78) 0.71 0.61 
Age of Symptom Onset 
(years)
 
34.4 (88) 36.07(15) 0.62 N/A N/A N/A N/A 
Age of  Diagnosis (years) 37.69(83) 39.93(14) 0.48 N/A N/A N/A N/A 
EDSS score 3.78 (43) 4.30 (5) 0.58 N/A N/A N/A N/A 
Biochemical indicators   
 
  
 
 
Serum iron (µmol/L) 16.90(89) 18.94(15) 0.31 16.1 (39) 20.5 (20) 0.02 0.77 
Serum transferrin (g/L) 2.65 (88) 2.56 (15) 0.52 2.71 (39) 2.51 (20) 0.005 0.94 
Transferrin saturation (%) 26.43(91) 29.65(15) 0.38 24.72 (79) 33.47 (35) 0.0002 0.62 
Serum ferritin (µg/L) 
89.21 
(105) 
250.93 
(15) 
0.01 
105.63 
(131) 
274.67 
(55)  
<0.0001 0.57 
Lifestyle habits         
≥5 fruit and/vegetables 
daily (score) 
4.77 (61) 5.00 (7) 0.79 4.61 (102) 4.76 (41) 0.71 0.67 
Red meat intake (score) 1.85 (61) 1.86 (7) 0.99 2.38 (102) 2.85 (41) 0.10 0.03 
Current cigarette smoker 
(yes) 
13  3  
 
18  11  
 
0.04 
Alcohol intake (score) 0.77 (57) 1.29 (7) 0.14 1.26 (102) 1.50 (40) 0.15 0.07 
Physical activity (score) 1.90 (61) 2.29 (7) 0.40 2.41 (103) 2.68 (41) 0.19 0.07 
Abbreviations: MS, multiple sclerosis. For the 48 MS patients from a previous study (Kotze 
et al. 2001) the lifestyle factors were not documented at the time of sample collection. 
 
The influence of non-genetic factors on iron parameters in MS patients and controls are 
shown in Table 3.3 for study participants where these were documented at entry into the 
study. Significant correlation between red meat intake and physical activity levels with serum 
ferritin and transferrin saturation were observed in controls (p≤0.01), but not in the MS 
patients (p>0.05), while BMI was associated with several iron parameters in both MS patients 
and controls. These modifiable lifestyle factors were therefore also considered as potential 
confounders during subsequent statistical analysis, where appropriate.  
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Table 3.3. P-values for Spearman rank-correlations determined to evaluate the relationship 
between non-genetic factors and iron parameters as assessed in a subset of 68 MS patients 
and 143 controls. 
 
MS patients Controls  
Serum 
iron 
Serum 
transferrin 
Transferrin 
saturation 
Serum 
ferritin 
Serum 
iron 
Serum 
transferrin 
Transferrin 
saturation 
Serum 
ferritin 
BMI 0.02 0.09 <0.01 0.73 0.02 0.32 0.02 <0.01 
Dietary 
red meat 
intake  
0.32 0.69 0.45 0.21 0.84 0.32 0.69 0.01 
Weekly 
alcohol 
intake  
0.47 0.96 0.61 0.48 0.90 0.73 0.97 0.42 
Physical 
activity 
level  
1.00 0.95 0.86 0.20 0.24 0.72 <0.01 0.71 
Abbreviation: BMI, body mass index 
 
 
Genetic analysis 
The genotypic distribution and allele frequencies of TMPRSS6 A736V (Figure 3.6) and HFE 
C282Y (Figure 3.7) did not differ significantly between patients and controls. There was also 
no significant difference in the combined genotype distribution of these mutations between 
patients and controls (data not shown). Due to the small number of individuals with the 
genotype combination TMPRSS6 CC/HFE GA, these 4 patients and 7 controls were 
excluded in Figure 3.8, showing the study groups used for the genotype-phenotype 
association study presented in Figure 3.9. The combined effect of TMPRSS6 A736V and 
HFE C282Y is shown in relation to serum ferritin levels, demonstrating a significantly lower 
concentration in MS patients with the TMPRSS6 CT/HFE GA and TMPRSS6 TT/HFE GA 
genotype combinations compared with the other genotype combinations (P<0.01). This 
significant reduction in log-ferritin was only observed in MS patients (p=0.03) but not controls 
(p>0.05), and remained significant after adjustment for age (p=0.01), BMI (p=0.04), and 
dietary red meat intake (p=0.04). This significant effect was also confirmed in females only, 
which excluded sex as a possible confounder. 
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Figure 3.8 Distribution of TMPRSS6 A736V / HFE C282Y combined genotypes determined 
in 114 MS patients and 176 controls.   
 
 
As shown in Figure 3.9 the TMPRSS6 CT/HFE GA and TMPRSS6 TT/HFE GA genotype 
combinations were associated with a significant decrease in log-ferritin level when compared 
to wild-type TMPRSS6 CC homozygotes for MS patients but not controls (p=0.027). The 
initial question which prompted the investigation of the combined effects of the TMPRSS6 
and HFE SNPs was apparently reduced penetrance of HFE C282Y in MS patients (Kotze et 
al. 2006). In this study it was found that in the presence of the TMPRSS6 T-allele (CT/TT 
genotype) in patients carrying the risk-associated A-allele of the HFE C282Y mutation (which 
is more likely expected to result in increased ferritin), ferritin levels were reduced.  
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Figure 3.9. Effect of combined TMPRSS6 and HFE genotypes on log-ferritin levels in MS 
patients compared with controls. The a and b labels indicates post-hoc test differences 
between genotypes. 
 
The same iron lowering trend was also seen for transferrin saturation in TMPRSS6 TT/HFE 
GG (21.45 %; 95% CI 16.24-26.6) vs the TMPRSS6 CC/HFE GG wild type genotype 
combination (29.26 %; 95% CI 24.66-33.88. This association became significant when the 
LSD Post Hoc Test was applied (p = 0.028). 
 
HFE C282Y is expected to increase serum ferritin and transferrin saturation levels (Allen et 
al. 2008), rather than reducing it as found for ferritin in MS patients in this study. In the HFE 
C282Y heterozygous MS patients serum iron and transferrin saturation were not increased 
compared to the wildtype GG genotype, while serum ferritin was significantly lower in GA 
heterozygous MS patients (44.6 µg/L; 95% CI 27.9-61.3) than in MS patients with the GG 
wildtype genotype of HFE C282Y (119.8 µg/L; 95% CI 99.7-139.9; p < 0.01). In this 
comparison the HFE C282Y homozygotes (AA genotype) were excluded due to small 
sample size (2 patients only) and association of this genotype with the most common form of 
hereditary haemochromatosis showing an autosomal recessive inheritance pattern as 
confirmed in South African patients (de Villiers et al. 1999) and many other studies 
worldwide.  
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Similar to the gene effect in the general population reported in the literature and our control 
samples (data not shown), serum ferritin was lower in patients with the TT genotype of 
TMPRSS6 A736V (86.6 µg/L; 95% CI 53.9-119.4), but not significantly different from the total 
group of MS patients with the CC wild type genotype (122.2 µg/L; 95% CI 82.3-162.1).  
Similarly, the serum iron concentration of MS patients with the TT genotype of TMPRSS6 
A736V was lower (14.28 µmol/L, 95% CI 11.95-16.60 µmoles/L) than the serum iron 
concentration of patients with the wild-type CC genotype (18.59 µmol/L, 95% CI 16.04-21.14 
µmoles/L), at a significance of p = 0.081 for the trend, as calculated by the Kruskal-Wallis 
test. This difference between the CC and TT genotypes of TMPRSS6 A736V became 
significant when the p value was calculated by the LSD Post Hoc Test (p=0.029). When the 
female patients (n=89) were considered separately to exclude the effect of gender on serum 
iron levels, the Post Hoc Test remained significant for the difference between TT and CC. 
The percentage transferrin saturation of patients with the TT genotype of TMPRSS6 A736V 
was also lower (22.4 % 95% CI 18.4-26.4 %) than that of patients with the wild-type CC 
genotype (29.7 %, 95% CI 25.1 – 34.2 %), at p = 0.102, as calculated by the Kruskal-Wallis 
test. The difference between the CC and TT genotypes of TMPRSS6 A736V became 
significant when the p- value was calculated by the LSD Post Hoc (p = 0.034). When 
determined in female patients only, although the patients with the TT variant still had lower 
transferrin saturation than those with the CC genotype, this difference was no longer 
significant. When the serum iron concentrations in MS patients were investigated 
differentially, a trend was found that patients with the TMPRSS6 TT/HFE GG genotype 
combination had lower serum iron concentrations (14.3 µmol/L; 95% CI 11.3-17.3) than 
patients with both the TMPRSS6 and HFE wild type CC/GG genotype combination (18.2 
µmol/L; 95% CI 15.6-20.9; p = 0.28). This became marginally significant when the LSD Post 
Hoc Test was applied (p = 0.05), possibly indicating that the iron-lowering effect of 
TMPRSS6 A736V (C>T) is stronger than the iron-increasing effect of HFE C282Y (G>A) in 
MS patients.  
 
A non-significant trend towards an earlier age of symptom presentation was noted in 103 MS 
patients homozygous for the risk-associated T-allele of TMPRSS6 A736V or heterozygous 
for the HFE C282Y (data not shown). The influences of combined TMPRSS6 A736V and 
HFE C282Y genotypes on age of onset and degree of MS disability are summarized in Table 
3.4 in a subset of MS patients who provided this information at entry into the study. When 
considered together, MS patients with the TMPRSS6 CT/HFE GA and TMPRSS6 TT/HFE 
GA genotype combinations had a significantly lower age of symptom onset (30 years, 95% 
CI 24 – 37 years) than patients the wild type TMPRSS6 CC/HFE GG genotype combination 
Stellenbosch University  http://scholar.sun.ac.za
48 
Chapter 3: Results 
(39 years 95% CI 34 – 44 years); p = 0.04 after applying the LSD post hoc test. A non-
significant trend-association was also found between decreased ferritin levels and an earlier 
age of symptom onset (p=0.08) after exclusion of the two HFE AA homozygotes.   
 
 
Table 3.4. Influence of TMPRSS6 A736V and HFE C282Y genotypes on age of onset and 
degree of MS disability in MS patients.  
(n) 
MS patients 
P-value 
Post-hoc 
CC/GG vs. 
CT/GA & 
TT/GA 
CC/GG 
CT/GA & 
TT/GA 
CT/GG TT/GG 
Age of 
symptom 
onset 
(years) (103) 
38.78 30.17 34.16 33.17 0.177 0.040 
Age of 
diagnosis 
(years) (97) 
41.27 38.85 36.51 36.69 0.373 0.519 
EDSS 
(score) (48) 
4.33 4.88 3.37 3.25 0.224 0.577 
Abbreviation: EDSS; expanded disability status scale 
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The focus of the present study was to evaluate combined effects of the low-penetrance 
TMPRSS6 A736V and HFE C282Y variants with opposite effects on iron metabolism in 
patients with MS, in an attempt to clarify the role of iron dysregulation in the disease process. 
The study population included 121 Caucasian MS patients and 286 population-matched 
controls. In order to exclude race as a confounder, 19 non-Caucasian individuals were 
excluded from the initial MS study cohort. Subgroup analyses were performed in relation to 
variables where full data sets were not available for all individuals. Serum iron, transferrin, 
ferritin and transferrin saturation levels were available from previous studies and lifestyle 
factors were subsequently documented in a subgroup of 68 MS patients and 143 controls 
using the study questionnaire. Genotyping of TMPRSS6 A736V and HFE C282Y were 
performed using allele-specific TaqMan technology after successful optimisation of this high 
throughput genotyping method in our laboratory.   
 
When genetic tests are performed for variants with low penetrance, such as TMPRSS6 
A736V and HFE C282Y, it is imperative that the tests or genetic markers are clinically 
validated and also comply with clinical utility and laboratory validation or optimisation 
requirements. Clinical validity refers to how well the test results detect or predict an 
association with the phenotype or disease, while clinical utility refers to the ability to prevent 
disease or administer therapies to remove or reduce the risk of the associated phenotype or 
disease. These were important considerations for justification of this study as neurologists 
are increasingly being made aware that they need to test for iron deficiency at diagnosis of 
MS. However, mostly only haemoglobin, and infrequently, ferritin determinations are 
requested. Therefore, application of a PSGT strategy aimed at early detection of a genetic 
predisposition for iron deficiency in a subgroup of MS patients (Kotze et al. 2009; van 
Rensburg et al. 2012) may provide an added incentive for clinicians to determine the need 
for iron supplementation in MS patients. Correcting iron deficiency at first disease 
presentation and monitoring of iron parameters over time may prevent future relapses and 
prevent disease progression, as evidenced in children with MS (van Toorn et al. 2010).  
 
MS is a severely debilitating and progressive neurological disorder associated with significant 
morbidity and early mortality worldwide. None of the DMDs for MS has to date obtained 
licensed approval for improving or reducing disability in MS (Tremlett et al. 2012). Based on 
these observations, there currently exists a growing need to identify genetic risk factors 
which may be triggered by environmental exposures or lifestyle habits that could aid the 
development of diagnostic or therapeutic algorithms which could potentially decrease 
symptom severity and increase quality of life in MS patients. The genotype and allele 
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frequencies of TMPRSS6 A736V are described here for the first time in South African MS 
patients and unaffected controls, while the prevalence of HFE C282Y has been described 
previously (de Villiers et al. 1999; Kotze et al. 2006) and confirmed in this study. TMPRSS6 
A736V is common in the general population, with previous studies indicating a prevalence of 
45% for the risk-associated T-allele (Nai et al. 2011). This correlates with the estimated 45% 
minor allele frequency of TMPRSS6 A736V in MS patients and 43% in the South African 
Caucasian controls studied, with genotype distributions also found to be similar in both 
groups.  
 
Multiple previous studies have demonstrated and subsequently confirmed associations 
between the minor allele of TMPRSS6 A736V and reduced iron parameters, ineffective 
erythropoiesis and an increased risk of developing iron deficiency (Benyamin et al. 2009; 
Tanaka et al. 2010; An et al. 2012). These effects are particularly relevant in light of the 
significant influence of iron regulation on remyelination capacity in MS and its relationship 
with disease and disability progression (Rooney et al. 1999; van Rensburg et al. 2006; van 
Rensburg et al. 2012). Significant correlations between homozygosity for the minor allele (TT 
genotype) of TMPRSS6 A736V and reduced iron levels and transferrin saturation are 
therefore in accordance with these previous results. Associations determined between this 
variant and a trend for earlier age of symptom presentation, which became significant in the 
presence of HFE C282Y (p<0.04), are also indicative of an accelerated disease process 
underlying earlier onset and clinical detection of MS in this genetic sub-group of patients. 
These findings also correlate with previous studies which suggest that reduced iron levels 
correlate with earlier clinical onset in MS (Van Rensburg et al. 2006).  
 
The results of the present study confirmed that TMPRSS6 A736V is associated with 
decreased serum concentrations of iron and transferrin saturation in MS patients and 
controls, similar to previous findings in the general population. Unexpectedly, however, 
genetic variation in the HFE gene produced a significant decrease in serum ferritin, only in 
the MS patients but not in the controls. HFE C282Y is usually associated with increased 
ferritin, while this gene effect appears to be modified in MS patients (Kotze et al. 2006). 
About 87% of patients who have hemochromatosis with high transferrin saturation and high 
serum ferritin have genetic variations in the HFE gene, while being homozygous for HFE 
C282Y was shown to have a greater effect towards  documented iron-overload-related 
disease in men (28.4%) than in women (1.2%) (Allen et al. 2008). Since this genotype is 
associated with an autosomal recessive type of haemochromatosis that may cause organ 
damage, if left untreated in patients diagnosed with this condition, individuals with two copies 
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of the faulty gene were excluded from comparative studies involving serum iron parameters 
in relation to TMPRSS6 A736V. Although this SNP is associated with iron deficiency in the 
general population it has not been associated with a specific clinical diagnosis of disease 
similar to the wide spectrum of clinical manifestation associated with homozygosity for HFE 
C282Y in the presence of high iron stores (due to gene-gene and gene-environment 
interaction). 
 
In the present study we found that both the TT genotype of TMPRSS6 A736V and the GA 
genotype of HFE C282Y are associated with earlier age of symptom onset in MS, and that 
when these two variants were simultaneously present, the effect became statistically 
significant (p=0.04). An explanation of these effects would have to be sought by considering 
the individual effects of the two variants. Although variation in the HFE and TMPRSS6 genes 
affect expression of hepcidin, the major iron regulatory protein, association of common 
variants in these genes with iron parameters may also occur independent of serum hepcidin 
in the general population (Galesloot et al. 2013).  The results presented in the present study 
indicate that in combination, the minor alleles of TMPRSS6 A736V and C282Y are 
associated with decreased iron concentrations in MS patients; TMPRSS6 possibly by partly 
blocking iron absorption and HFE unexpectedly decreasing ferritin levels by an unknown 
mechanism that may involve the inflammatory response. All other iron parameters analysed 
in MS patients, including serum iron and transferrin saturation, were increased in MS patients 
with the HFE C282Y mutation as would be expected (data not shown), although these 
differences did not reach statistical significance.  
 
Based on our findings it may be speculated that HFE C282Y may exert its effect in MS 
patients on the synthesis of serum ferritin, which is primarily derived from macrophages 
(Cohen et al. 2010). Drakesmith et al. (2005) showed that the expression of HFE (a MHC Ib 
protein) in macrophages may be downregulated by a protein associated with the HIV 
retrovirus. The association between HFE and inflammation has previously been highlighted 
(Kotze et al. 2003, 2006), while a connection between retroviral infection in MS has been 
shown as well in South African MS patients (de Villiers et al. 2006). Perron et al. (2012) 
detected antigen to the ENV protein of the Human Endogenous Retroviral family 'W' (HERV-
W) in peripheral blood mononuclear cells (PBMCs) of 73% of patients with MS, but not in 
chronic infection, systemic lupus, most other neurological diseases and healthy donors. 
HERV-W was also present in macrophages within MS brain lesions and in macrophages in 
the vicinity of cerebral blood vessels. Whether HERV-W interacts with HFE to exert an effect 
on ferritin production in these macrophages as well remains to be established. Ferritin 
Stellenbosch University  http://scholar.sun.ac.za
52 
Chapter 4: Discussion and Conclusion 
donates iron to myelin-producing oligodendrocytes (Hulet et al. 2000; Todorich et al. 2011); 
therefore it may be hypothesized that a decrease in ferritin would impact myelin production.  
 
The combined effect of the HFE and TMPRSS6 genotypes on serum ferritin is of particular 
interest as previous studies have shown that South African MS patients with genetic HH i.e. 
C282Y homozygotes presenting with elevated transferrin saturation and ferritin levels, do not 
manifest organ damage such as hepatic dysfunction characteristic of the disease, as well as 
showing fewer clinical manifestations (Kotze et al. 2006). These results led us to speculate 
that unknown genetic variations implicated in iron, inflammatory and/or immune 
dysregulation might affect the penetrance of genetic HH or disease expression of MS 
separate from known environmental risk factors (Kotze et al. 2006). Subsequently, it was 
discovered that deleterious mutations in the TMPRSS6 gene cause iron-refractory iron 
deficiency anaemia (IRIDA) (Finberg et al. 2008). While it is possible that this may relate to 
increased expression of pro-inflammatory cytokines in MS, further evaluation thereof was 
beyond the scope of the current study.  
 
In light of the iron-lowering effect of the minor T-allele of TMPRSS6 A736V despite co-
inheritance of the HFE G>A mutation, it may be hypothesized that the interaction between 
these genes could at least in part explain the previously noted lack of clinic manifestation of 
HH commonly observed in MS patients as reported by Kotze et al. (2006). The index case in 
this study was diagnosed with both MS and haemochromatosis, but showed a lack of clinical 
manifestation of inherited iron overload. In the present study it was found that this patient is 
homozygous for the TMPRSS6 polymorphism (data not shown).  
 
Epistatic gene-gene interactions are increasingly recognised as primary drivers of the 
phenotypic expression of chronic, non-communicable diseases (NCD) such as MS and 
haemochromatosis. Despite the promise that new developments towards routine application 
of whole exome/genome sequencing techniques could overcome the limitations of targeted 
SNP genotyping (Kotze and Gamieldien 2013), the clinical relevance of the combined effect 
of TMPRSS6 A736V and HFE C282Y may have remained undetected without the pre-
existing knowledge driven PSGT approach applied in this study (van Rensburg et al. 2012). 
This concept has been developed over the course of the preceding decade (Kotze et al. 
2013) after careful consideration of ethical issues related to potential genetic discrimination 
(Kotze et al. 2004). The PSGT concept was developed based on our experience in patients 
suspected to have HH, which provides a fitting example of the use of genetics in a complex 
multifactorial disease in general (Kotze et al. 2009). By considering HFE genotyping in 
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relation to iron parameters to confirm the diagnosis and aid the formulation of tailored 
management strategies, HFE genotyping translated into a rapid genetic test applied routinely 
in South Africa from 1999 (de Villiers et al. 1999). While implementation of HFE genotyping 
resulted in significant reduction of invasive liver biopsies during clinical work-up towards a 
diagnosis of HH, it remains unknown to what extent personalized genomics for other iron-
related conditions could benefit existing management strategies either in the general 
population or MS patients with iron deficiency. A greater understanding of gene-gene and 
gene-environment interaction relevant to both MS and HH could benefit our understanding of 
iron regulatory pathways and may lead to the development of novel therapies for these 
conditions in future.  
 
In the present study patients with MS displayed lower dietary intake of red meat compared to 
controls, which may impact on availability of iron in the diet, particularly in a subset of 
patients with increased requirements due to a genetic predisposition for iron deficiency. 
While genetic anaemia may be caused by a variety of missense mutations in the TMPRSS6 
gene (De Falco et al. 2013), it is well known that many other pathological or environmental 
factors could contribute towards treatment-resistant IDA, including malabsorpsion states and 
gastrointestinal tumours. It is interesting to note that TMPRSS6 also plays a role in a 
microcytic anaemia associated with progressive iron overload and hepcidin deficiency, i.e. 
beta thalassemia intermedia (Guo et al. 2013). It cannot therefore be assumed that all cases 
of IDA resistant to oral iron supplementation are due to high impact mutations or functional 
SNPs in the TMPRSS6 gene. It also remains unknown how many patients with treatment-
resistant IDA will have the low-penetrance mutation in the TMPRSS6 gene investigated here, 
since at least 40 mutations have been described to date in this gene (De Falco et al. 2013). 
The SNP studied here contributes significantly to iron deficiency in the general population, 
while complete disruption of TMPRSS6 has a dominant effect over that of HFE on the 
regulation of iron metabolism (Finberg et al. 2011, Valenti et al. 2012) that may be of more 
relevance in a family context.  
 
Results presented in this study confirmed the serum iron and transferrin saturation lowering 
effect of TMPRSS6 A736V in the South African Caucasian population. Interaction between 
this functional polymorphism and HFE C282Y may account for the significant ferritin-lowering 
effect observed in MS patients and could at least partly explain the low penetrance and lack 
of phenotypic expression of genetic HH previously observed in MS patients (Kotze et al. 
2006). Just as PSGT has shown considerable advantages in the formulation of a cost-
effective and timely therapeutic strategy to HH, it seems likely that consideration of the 
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TMPRSS6 and HFE genotypes in relation to serum iron parameters and diet could help 
stratify MS patients with regards to the need and predictive response to iron supplementation 
to limit disability progression and improve disease outcomes in these individuals, with 
potential applications for iron deficiency in the general population in future. Higher dietary red 
meat intake correlated significantly with increased ferritin only in controls (p=0.01 vs. 0.21 for 
MS patients). This result may be related to the significantly lower intake of red meat in MS 
patients compared with controls (p=0.03) and/or reflect a different response to dietary iron 
intake in MS patients due to the genetic background. The potential benefit of iron 
supplementation in MS patients with an apparent iron deficiency subtype of MS has recently 
been substantiated by exome sequencing (Jalali et al. 2012; Kotze and Gamieldien 2013) in 
the index case described by Rooney et al. (1999) as well as the children with MS studied by 
van Toorn et al. 2010).  Various high-impact deleterious mutations involved in iron regulation 
and homeostasis were identified in these MS patients in addition to variation in the 
TMPRSS6 gene. 
 
The above-mentioned results were obtained despite several limitations, which can be 
summarised as follows: 1) biochemical testing of iron parameters was not performed in the 
same laboratory for all samples as these were available from previous studies performed in 
different laboratories; 2) only two iron-related genes were investigated in this study, which 
could underestimate the risk of combined effects exerted by multiple functional 
polymorphisms; and 3) determining MS onset by definitive diagnosis or onset of first 
symptoms may be affected by various factors and therefore rigorous case definitions and 
consideration of differences between clinical subtypes are recommended for future studies. 
 
We conclude that the results obtained in this study confirm that genotype associations 
cannot always predict biochemical phenotypes; therefore measurement of iron parameters in 
MS patients was important to determine the mechanism underlying the link between iron-
related genes and earlier age of onset of MS. Gemmati et al. (2012) reported an association 
between disability progression rates and variation in the HFE gene in MS patients, leading 
them to speculate that iron overload may be involved in accelerated disease progression. 
However, these authors did not present data on serum iron parameters which is a limitation 
as the present study indicated that there may paradoxically be an inverse effect on iron 
status in MS patients with the HFE C282Y mutation. This mutation was found to be 
associated with earlier development of MS in this study when ferritin levels are reduced 
possibly as a consequence of co-inheritance with TMPRSS6 A736V in a subgroup of MS 
patients with a compromised immune system. The clinical usefulness of the PSGT concept 
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for MS (van Rensburg et al. 2012) was confirmed as it would not have been possible to 
explain the results obtained in this study without the application of a multidisciplinary 
approach. 
 
When a low penetrance mutation / functional polymorphism such as TMPRSS6 A736V or 
HFE C282Y are detected in a DNA sample, it does not mean that the individual will 
necessarily develop the associated disease. The individual may however be vulnerable to 
environmental triggers that can interact with the genetic risk factor and together contribute to 
disease development. It is therefore important to know whether environmental factors are 
involved in disease expression prior to genetic testing and to understand the mechanisms of 
action as a consequence of gene-gene and gene-environment interactions considered in this 
study in relation to iron metabolism. Although prolonged periods of exposure could worsen 
the severity of disease in genetically compromised individuals, most environmental risk 
factors can be modified or avoided. Genetic testing therefore provides an opportunity for 
early awareness and guidance, since it is only when people are well informed that they are 
able to take proper preventive measures or receive targeted treatment tailored to individual 
needs.  
 
In summary, our results may indicate an epistatic effect between TMPRSS6 A736V and HFE 
C282Y associated with reduced ferritin levels in MS patients. This finding confirms the role of 
TMPRSS6 A736V as a genetic modifier of hereditary haemochromatosis, correlating with a 
lack of clinical manifestation of HFE C282Y in a subgroup of MS patients. It also highlights 
the value of pathology-supported genetic testing as a new concept that is well placed to 
optimise clinical benefit in patients with iron-related disorders. 
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KURTZKE EXPANDED DISABILITY STATUS SCALE (EDSS) AND 
FUNCTIONAL SYSTEMS SCORES (FSS) 
 
Patient……………………………………………………………………………………….. 
Date………………………………… 
Examiner………………………………………………………………………. 
Final score………………………………………… 
 
The Kurtzke Expanded Disability Status Scale (EDSS) 
 
Disability 
score 
Neurological status 
  0.0 Normal neurological examination (all grade 0 in all Functional System (FS) scores) 
(Excludes cerebral function grade 1) 
  1.0 No disability, minimal signs in one functional score (FS) (i.e. grade 1) 
  1.5 No disability, minimal signs in more than one FS (more than 1 FS grade 1) 
  2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1) 
  2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1) 
  3.0 Moderate disability in one FS (one FS grade 3, others 1 or 0), or mild disability in 
three or four FS (three or four FS grade 2, others 0 or 1) though fully ambulatory 
  3.5 Fully ambulatory but with moderate disability in one FS (one grade 3) and one or 
two FS grade 2, or two FS grade 3 (others 0 or 1) or five grade 2 (others 0 or 1) 
  4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day 
despite relatively severe disability consisting of one FS grade 4 (others 0 or 1), or 
combination of lesser grades exceeding limits of previous steps; able to walk 
without aid or rest some 500 meters 
  4.5 Fully ambulatory without aid, up and about much of the day, able to work a full 
day, may otherwise have some limitation of full activity or require minimal 
assistance; characterized by relatively severe disability usually consisting of one 
FS grade 4 (others or 1) or combinations of lesser grades exceeding limits of 
previous steps; able to walk without aid or rest some 300 meters 
  5.0 Ambulatory without aid or rest for about 200 meters; disability severe enough to 
impair full daily activities (e.g. to work a full day without special provisions): (Usual 
FS equivalents are one grade 5 alone, others 0 or 1; or combinations of lesser 
grades usually exceeding specifications for step 4.0) 
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  5.5 Ambulatory without aid for about 100 meters; disability severe enough to preclude 
full daily activities (Usual FS equivalents are one grade 5 alone, others 0 or 1; or 
combination of lesser grades usually exceeding those for step 4.0) 
  6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk 
about 100 meters with or without resting; (Usual FS equivalents are combinations 
with more than two FS grade 3+) 
  6.5 Constant bilateral assistance (canes, crutches, braces) required to walk about 20 
meters without resting; (Usual FS equivalents are combinations with more than 
two FS grade 3+) 
  7.0 Unable to walk beyond approximately five meters even with aid, essentially 
restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up 
and about in wheelchair some 12 hours a day; (Usual FS equivalents are 
combinations with more than one FS grade 4+; very rarely pyramidal grade 5 
alone) 
  7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in 
transfer; wheels self but cannot carry on in standard wheelchair a full day; May 
require motorized wheelchair; (Usual FS equivalents are combinations with more 
than one FS grade 4+) 
  8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be 
out of bed itself much of the day; retains many self-care functions; generally has 
effective use of arms; (Usual FS equivalents are combinations, generally grade 4+  
in several systems) 
  8.5 Essentially restricted to bed much of day; has some effective use of arm(s), retains 
some self care functions; (Usual FS equivalents are combinations, generally 4+  in 
several systems) 
  9.0 Helpless bed patient; can communicate and eat; (Usual FS equivalents are 
combinations, mostly grade 4+) 
  9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow; 
(Usual FS equivalents are combinations, almost all grade 4+) 
  10.0 Death due to MS 
  
Note1: EDSS steps 1.0 to 4.5 refer to patients who are fully ambulatory and the precise step 
number is defined by the Functional System score(s). EDSS steps 5.0 to 9.5 are defined by 
the impairment to ambulation and usual equivalents in Functional Systems scores are 
provided. 
Note 2: EDSS should not change by 1.0 step unless there is a change in the same direction 
of at least one step in at least one FS. 
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The Functional Systems Scores (FSS) 
 
  Pyramidal Function 
0 - Normal 
1 - Abnormal signs without disability 
2 - Minimal disability 
3 - Mild to moderate paraparesis of hemiparesis (detectable weakness but most function 
sustained for short periods, fatigue a problem); severe monoparesis almost no function) 
4 - Marked paraparesis or hemiparesis (function is difficult); moderate quadriparesis (function 
is decreased but can be sustained for short periods) or monoplegia 
5 - Paraplegia, hemiplegia, or marked quadriparesis 
6 - Quadriplegia 
9 - Unknown  
 
  Cerebellar Function 
0 - Normal 
1 - Abnormal signs without disability 
2 - Mild ataxia (tremor or clumsy movements easily seen, minor interference with function) 
3 - Moderate truncal or limb ataxia (tremor or clumsy movements interfere with function in all  
     spheres) 
4 - Severe ataxia in all limbs (most function is very difficult) 
5 - Unable to perform coordinated movements due to ataxia 
9 - Unknown 
 
 - Record no 1 in small box when weakness (grade 3 or worse on pyramidal) interferes with 
testing 
 
  Brainstem Function 
0 - Normal 
1 - Signs only 
2 - Moderate Nystagmus or other mild disability 
3 - Severe Nystagmus, marked extraocular weakness, or moderate disability of other cranial 
nerves 
4 - Marked dysarthria or other marked disability 
5 - Inability to speak or swallow 
9 - Unknown 
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  Sensory Function 
0 - Normal 
1 - Vibration or Figure - writing decrease only in 1 or 2 limbs 
2 - Mild decrease in touch or pain or position sense, and/or moderate decrease in vibration in 
1 or 2 limbs, or vibratory (c/s Figure writing) decrease alone in 3 or 4 limbs 
3 - Moderate decrease in touch or pain or position sense, and/or essentially lost vibration in 1 
or 2 limbs; or mild decrease in touch or pain and/or moderate decrease in all proprioceptive 
tests in 3 or 4 limbs 
4 - Marked decrease in touch or pain or loss of proprioception, alone or combined in 1 or 2 
limbs; or moderate decrease in touch or pain and/or severe proprioceptive decrease in more 
than two limbs 
5 - Loss (essentially) of sensation in 1 or 2 limbs; or moderate decrease in touch or pain 
and/or loss of proprioception for most of the body below the head 
6 - Sensation essentially lost below the head 
9 - Unknown 
 
  Bowel and Bladder Function 
(Rate on the basis of the worse function, either bowel or bladder) 
0 - Normal 
1 - Mild urinary hesitancy, urgency, or retention 
2 - Moderate hesitancy, urgency, or retention of bowel or bladder, or rare urinary 
incontinence (intermittent self-catheterization, manual compression to evacuate bladder, or 
finger evacuation of stool) 
3 - Frequent urinary incontinence 
4 - In need of almost constant catheterization (and constant use of measures to evacuate 
stool) 
5 - Loss of bladder function 
6 - Loss of bowel and bladder function 
9 - Unknown  
 
  Visual Function 
0 - Normal 
1 - Scotoma with visual acuity (corrected) better than 20/30 
2 - Worse eye with scotoma with maximal visual acuity (corrected) 20/30 to 20/59 
3 - Worse eye with large scotoma, or moderate decrease in fields, but with maximal visual 
acuity (corrected) 20/60 to 20/99 
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4 - Worse eye with marked decrease of fields and maximal visual acuity (corrected) of 
20/100 to 20/200; grade 3 plus maximal acuity of better eye of  20/60 or less 
5 - Worse eye with maximal visual acuity (corrected) less than 20/200; grade 4 plus maximal 
acuity of better eye of  20/60 or less 
6 - Grade 5 plus maximal visual acuity of better eye of 20/60 or less 
9 - Unknown  
 
  Cerebral (or mental) Functions 
0 - Normal 
1 - Mood alteration only (does not affect EDSS score) 
2 - Mild decrease in mentation 
3 - Moderate decrease in mentation 
4 - Marked decrease in mentation (chronic brain syndrome – moderate) 
5 - Dementia or chronic brain syndrome – severe or incompetent 
9 - Unknown 
 
The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in 
multiple sclerosis (Kurtzke, 1983). The EDSS quantifies disability in eight Functional Systems 
(FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. 
The Functional Systems are: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, 
visual, and cerebral.    
 
Reference  
Kurtzke, J.F. 1983. Rating neurological impairment in multiple sclerosis: an expanded 
disability status scale (EDSS). Neurology, 33:1444-1452. 
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APPENDIX B 
 
Guidelines To McDonald Criteria 
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 TABLE: Recommendations List {adapted from the “Revisions to McDonald Diagnostic Criteria for Multiple sclerosis” (Polman et al. 2005)} 
Clinical presentation Additional data needed for MS diagnosis 
-Two or more episode of neurological disturbance for which causative 
lesions are likely to be inflammatory or demyelinating in nature (attacks) 
-Objective clinical evidence of two or more lesions 
No additional tests are recommended 
-Two or more attacks  
-Objective clinical evidence of one lesion 
Two or more MRI-detected lesions and positive CSF analysis (detection 
of oligoclonal bands)  
OR 
Dissemination in space demonstrated by MRI: Fulfilling at least three of: 
 one gadolinium enhanced lesion 
 one infratenotorial lesion 
 one juxtacortical lesion 
 three periventricular lesion  
OR 
Await further clinical attack 
-One attack 
-Objective clinical evidence of two or more lesions 
Dissemination in space demonstrated by MRI with previous criteria 
OR 
Await second clinical attack 
-One attack 
-Objective clinical evidence of one lesion (monosymptomatic presentation; 
clinically isolated syndrome) 
Dissemination in space demonstrated by MRI with previous criteria 
OR 
Two or more MRI-detected lesions consistent with positive CSF analysis 
And  
Dissemination in space demonstrated by MRI with previous criteria 
OR 
Second clinical attack 
-Insidious neurological progression One year disease progression and any two of the following: 
 positive brain MRI 
 positive spinal cord MRI (two focal T2 lesions) 
 positive CSF 
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